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Abstract 
Oxidative Damage and Selective Neuronal Vulnerability in Alzheimer’s Disease 
 
Jacqueline Starr Welty, PhD 
 
University of Pittsburgh, 2019 
 
 
 
 
Human cells are constantly under assault by damaging agents that arise from endogenous 
and exogenous sources. Damage to DNA is especially harmful because it encodes essential RNA 
molecules and proteins necessary for cellular functions. Failure to carry out sufficient DNA repair 
may compromise the genome and lead to the development of mutations and potential disease. 
Specifically, oxidative damage in the form of reactive oxygen species (ROS) and resulting DNA 
double strand breaks (DSBs) have been implicated in neurodegenerative diseases such as 
Alzheimer’s Disease (AD). Many cells, such as epithelial cells, are constantly replaced and do not 
need robust systems of repair. However, terminally differentiated and post-mitotic cells such as 
neurons must survive a lifetime and maintain genomic stability. How they manage to do so is still 
under investigation.  
For error-free repair of DSBs, homologous recombination (HR) can occur during the S/G2 
phases of the cell cycle utilizing a sister chromatid template. However, for post-mitotic cells such 
as neurons that cannot utilize a sister chromatid template, only the error-prone non-homologous 
end joining (NHEJ) pathway has been proposed. Recent studies in my lab have elucidated a novel 
RNA-templated recombination based repair pathway that occurs in the G0/G1 phase of the cell 
cycle. How post-mitotic terminally differentiated neuronal cells utilize these pathways has yet to 
be understood. 
The goal of my thesis is to understand how post-mitotic neurons maintain genomic 
integrity in repairing DSBs when faced with excessive oxidative damage. My preliminary studies 
have shown recruitment of transcription coupled homologous recombination (TC-HR) factor 
RAD52 to sites of DSB induced by laser microirradiation in primary post-mitotic rat cortical 
 v 
neuronal cells. This recruitment is largely dependent upon active transcription. How neurons 
utilize TC-HR proteins in DSB repair has yet to be elucidated. My main hypothesis is that 
terminally differentiated post-mitotic neurons utilize the TC-HR pathway to repair DSBs 
and maintain genomic integrity. To test this hypothesis, I investigated the roles of TC-HR 
associated proteins in post-mitotic neurons and how toxic soluble amyloid beta (Aβ1-42) oligomers 
compromise this pathway, which may lead to neurodegenerative pathologies seen in AD. 
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1.0 Introduction 
1.1 Alzheimer’s Disease 
1.1.1  Alzheimer’s Disease statistics and characteristics 
Alzheimer’s Disease (AD) is an irreversible neurodegenerative disorder that afflicts 
millions of people worldwide. It is the leading cause of dementia among the elderly, comprising 
approximately 60-80 percent of dementia cases. It currently has no cure. By 2025, it is estimated 
that the number of individuals over 65 with Alzheimer’s dementia will reach 50 million worldwide, 
a 35% increase from 2017. More women than men are affected by AD, but the reason for this 
remains unknown [1].  
In its early stages, AD is characterized by difficulty remembering recent conversations, 
names or events, along with apathy and depression. Late stage symptoms include impaired 
communication, disorientation, confusion, poor judgment, behavior changes and finally difficulties 
with motor movements such as coordination, walking, and swallowing. Later stage AD can lead 
to death due to immobility, swallowing disorders, malnutrition, and pneumonia [1, 2]. 
Characteristics of AD are typically analyzed post-mortem and consist of extracellular amyloid beta 
(Aβ) plaques and intracellular hyper-phosphorylated tau tangles in the brain. AD progresses 
throughout the basal forebrain, frontal lobe, cerebral cortex and hippocampal regions of the brain, 
leading to neuronal loss and synaptic dysfunction as the disease progresses [3-5]. Studies now 
indicate that AD can begin up to 20 years prior to the manifestation of symptoms [6-9].  
Currently, diagnosis of AD requires a comprehensive medical evaluation as there is no 
single test. The National Institute on Aging-Alzheimer’s Association has established updated 
criteria to assess AD in the elderly which now includes a pre-clinical stage and degrees of amyloid 
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accumulation, tau tangle-bearing neurons, and neuritic plaques [10]. These criteria help to 
distinguish AD from other neurologic diseases such as Parkinson’s and Lewy body disease.  
Tests for biomarkers such as Aβ have been recently developed and are currently being 
used in AD diagnosis. Structural imaging of the brain utilizing magnetic resonance imaging (MRI) 
or computed tomography (CT) scans can be used to identify brain atrophy associated with later 
stage neurodegeneration [11]. Imaging compounds such as Pittsburgh compound B, which 
selectively binds Aβ deposits and can be visualized using PET scans, can be used to detect 
earlier stages of AD [12]. Although there is no current cure or efficient treatment for AD, these 
diagnostic screens can assist with tracking and staging of the disease process, differential 
diagnosis, and identification of prodromal stages of neurodegeneration. They can also be helpful 
to establish clinical trials of treatments involving early stage AD patients in the hope of preventing 
the progression of the disease into irreparable neuronal degeneration.    
Studies have shown the accumulation of aggregated Aβ plaques found in AD patients has 
been associated with increased amounts of oxidative damage and consequent DSBs in the 
human brain [13, 14]. These Aβ aggregates primarily consist of the longer form of Aβ precursory 
product, Aβ1-42, as compared to the shorter, more commonly found Aβ1-40  [15]. DSBs are the most 
deleterious forms of DNA damage, and can lead to mutations, cellular senescence, and 
apoptosis. How Aβ1-42 is associated with DSB repair in post-mitotic neurons is generally unknown, 
such as whether this toxic precursory form of Aβ aggregates directly or indirectly affects repair 
processes, or affects the DNA itself through the production of ROS. Understanding the direct role 
of Aβ1-42 in DNA damage and repair will increase our understanding of other neurodegenerative 
diseases such as Parkinson’s disease which are also characterized by protein aggregates. 
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1.1.2  Alzheimer’s Disease associated mutations 
Only a small subset of AD cases is a result of identified inherited genetic mutations. 
Named early-onset familial AD (FAD), these constitute about 1% or less of all AD cases. They 
are the result of mutations in three genes: APP (amyloid precursor protein), PSEN1, and PSEN2 
(presenilin 1 and 2). Presenilin 1 and 2 are subunits of the γ-secretase complex, one of the 
secretase enzymes responsible for processing APP into soluble Aβ1-42 oligomers. Individuals with 
mutations in APP or PSEN1 are guaranteed to develop AD. Those with mutations in PSEN2 have 
a 95% chance of developing AD. Individuals with these specific mutations tend to develop AD 
well before age 65, typically around age 30, while the remaining population tends to develop late-
stage AD after age 65 [1]. Importantly, mice and rats do not produce Aβ that aggregates in the 
same manner as human Aβ found in AD pathology. Mouse and human APP differ by 17 amino 
acids, 3 of which are located in the Aβ region, thus affecting its cleavage and aggregation [16]. 
Therefore, in order to more accurately investigate AD pathology in a rodent model, transgenic 
mice and rats are engineered using these FAD mutations to create more accurate models for 
essential research. Individuals with trisomy 21, or an extra copy of chromosome 21, are also 
prone develop AD due to overexpression of the APP gene. Reports indicate that nearly all 
individuals with trisomy 21, or Down’s Syndrome, display AD neuropathology after age 40 due to 
higher amyloid plaque load and neurofibrillary tangles[17].    
Risk factors known to increase the likelihood of developing late-stage AD include type II 
diabetes, obesity, cardiovascular disease, smoking, lack of physical and mental activity, and 
hypertension [1, 18-20]. Individuals may also carry genetic risk factors such as specific isoforms 
of the apolipoprotein gene (APOE).  Unlike the APP and PSEN1 and PSEN2 mutations, however, 
having specific APOE isoforms does not guarantee the development of late-stage AD. The APOE 
gene codes for a protein that redistributes lipids (e.g.- cholesterol) in the central nervous system 
(CNS), and is normally synthesized and secreted by astrocytes[21]. There are three isoforms of 
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APOE which differ in single amino acid substitutions: ε2, ε3, or ε4, one of which is inherited from 
each parent. The most common isoform is ε3, with ε2 being the least common. Having the ε2 
isoform may decrease one’s risk of developing AD, while having one allele of the ε4 isoform 
increases one’s risk by threefold compared to having two alleles of the ε4 isoform, which increases 
one’s risk by eight to twelve fold. In vitro studies associated apoε3 and apoε2 with the production 
of long neurites, while apoε4 was associated with an inhibition of neurite outgrowth [22-24]. This 
association was specific to microtubule assembly in that apoε3 would stimulate the polymerization 
of β-tubulin and stabilize the formation of microtubules, and apoε4 would destabilize their 
formation. It was hypothesized that since apoε3 preferentially interacts with tau, it may protect tau 
from hyper-phosphorylation, one of the hallmarks of AD pathology [24, 25]. Another hypothesis 
states that low levels of apoε as seen in apoε4 carriers would lead to impaired clearance of soluble 
Aβ1-42. This is a pathology reported in the cortex and hippocampus of apoε4/AD patients, and is 
based upon research findings postulating that apoε lipoprotein complexes bind to the lipophilic 
portion of soluble Aβ (localized in the amino acid 18–42 portion of the peptide) and clear it from 
the extracellular space [26].   
In FAD mutations which lead to early onset AD, many contribute to increased Aβ1-42 levels 
due to mutations in APP or its cleavage. However, these mutations are not present in late-stage 
AD.  Aβ deposits have been associated with elevated levels of Aβ1-42 in transgenic rodent models 
expressing human APP [27]. The accumulation of extracellular Aβ1-42 has also been associated 
with both the seeding and further deposition of long and short forms of Aβ [28, 29]. Therefore, not 
only is the production of Aβ and its precursors relevant in understanding the development and 
pathology of AD as seen in the FAD associated mutations, but as illustrated in the case of apoε, 
clearing mechanisms of Aβ and its precursors before aggregation products develop is also 
essential to our understanding in order to develop strategies to prevent this devastating disease.  
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1.2 Tau pathology 
Tau is a microtubule–associated protein (MAP) that stimulates tubulin assembly into 
microtubules in the brain. The single tau gene encodes six isoforms as a result of alternative 
splicing, all of which are expressed in the adult human brain [30]. Its reported beneficial effect is 
to stabilize microtubules, promoting neuritic extension and stabilization. A negative effect of tau 
is its competition with the motor protein kinesin, which could lead to decreased axonal transport 
[31-33].  
Tau can be post-translationally modified in numerous ways including phosphorylation, 
glycosylation, ubiquitination, polyamination, nitration, truncation, and aggregation. However, the 
hyper-phosphorylation of tau has most strongly been implicated in the pathology of AD [34]. 
Phosphorylation sites implicated in AD include Ser199/Ser202/Thr205, Thr212, Thr231/Ser235, 
Ser262/Ser356, and Ser422 which have been found to convert tau to an inhibitory molecule that 
sequesters normal microtubule-associated proteins from microtubules [35]. Phosphorylation at 
Thr231, Ser396, and Ser422 promotes the self-aggregation of tau into filaments, impacting its 
activity and disrupting microtubules [36]. How abnormal tau leads to toxicity isn’t fully understood. 
Some studies have shown a gain in toxic ability of abnormal hyper-phosphorylated tau to 
sequester normal tau and other microtubule associated proteins, leading to microtubule 
disassembly [37-39]. More recent studies have even begun probing correlations between amyloid 
beta protein (Aβ) and tau hyper-phosphorylation, and whether one may contribute to the other. 
For example, a study found aggregated Aβ peptides induced tau phosphorylation in primary rat 
neuronal cultures [40]. For the purposes and simplicity of this thesis, however, we focused on 
Aβ’s role in AD pathology. 
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1.3 The amyloid beta hypothesis 
1.3.1  Amyloid beta processing 
The amyloid precursor protein (APP), a transmembrane protein consisting of 695-770 
amino acids involved in neurodevelopment, synaptogenesis, and cell adhesion, is proteolytically 
processed along two separate pathways: 1) the amyloidogenic, which leads to amyloid beta (Aβ) 
production, and 2) the non-amyloidogenic pathway [41-44]. As illustrated in Fig. 1-1, in the non-
amyloidogenic pathway, APP cleavage is mediated by α-secretases (ADAM9, ADAM10, or 
ADAM17),  releasing: the larger soluble ectodomain sAPPα. The membrane-anchored carboxy-
terminal domain of C83 can undergo further cleavage by γ- secretase to produce p3 [45, 46], an 
innocuous fragment. In the amyloidogenic pathway, β- secretase (BACE1) first cleaves APP to 
release an ectodomain (sAPPβ), leaving 99 amino acids of APP within the membrane (C99). C99 
is then cleaved by γ- secretase 38-43 amino acids from the N-terminus to produce Aβ [43, 44, 
47]. The final cleavage of Aβ produces fragments which vary in length from 37-43 amino acids.  
The longer Aβ peptides, including Aβ1-42, are more hydrophobic and more prone to aggregate in 
the brains of AD patients. Low concentrations (pM) of Aβ1-42 have been confirmed in the interstitial 
fluid of normal brains by microdialysis, but higher concentrations in the nM-μM range lead to 
neurotoxicity and neuronal death [48, 49]. 
It is only partially known what triggers the amyloidogenic vs the non-amyloidogenic 
pathway in neurons: the α-secretases, which cleave APP along the non-amyloidogenic pathway, 
are more abundant than the β-secretases, which cleave APP in the amyloidogenic pathway [50-
52]. However, what function Aβ1-42 serves is not clear.  
 
 9 
 
Figure 1-1 The amyloidogenic pathway of Aß production. 
In the amyloidogenic pathway, amyloid precursor protein (APP) is cleaved by β-secretase (BACE1) and γ-
secretase to generate amyloid-beta fragments ranging in size from 38-43aa. These aggregate outside the 
cells into oligomers, and further aggregate into fibrils and plaques. 
 
1.3.2  Amyloid beta as a metallo-protein 
Free metals such as Fe, Cu, and Zn are essential for numerous functions in the brain such 
as neuronal transmission, oxygen transport, and electron transfer. Maintaining homeostasis of 
these metals and their reduced/oxidized forms is critical. Aβ has been implicated in numerous 
interactions with Fe, Cu, and Zn, both in beneficial and detrimental ways. For example, prior 
research has found that Fe2+ concentrations are higher in advanced AD brains than in normal 
patients [53]. Iron plays an extensive role in the production of oxidative stress by the formation of 
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a hydroxyl radical via the Fenton reaction. Here, Fe2+ is reduced to Fe3+ by O2, producing O2-. O2- 
then reacts with H+ and produces H2O2, which reacts with Fe2+ and produces hydroxyl radicals 
[54]. These chemically reactive hydroxyl radicals in turn generate lipid peroxidation products, 
protein carbonyl modifications, and nucleic acid adducts such as 8-hydroxyguanosine (8-OHG) 
which have all been implicated as characteristic of AD neuropathology [55, 56]. In vitro studies 
have also showed that Fe induces Aβ aggregation and tau hyper-phosphorylation [57, 58].  
Cu can be distributed differently throughout each brain region. However, overall levels of 
Cu are found to be lower in the cerebral cortex of AD patients compared to healthy patients, 
hypothetically due to the association of Cu to aggregated Aβ plaques and its depletion from the 
surrounding tissue and cells [59, 60]. Cu is known to directly bind Aβ. This Cu- Aβ peptide then 
produces H2O2 through the reduction of Cu2+ to Cu3+ and the production of hydroxyl radicals [61]. 
The redox activity of Aβ is greatest for Aβ1-42, largely mediated by the Cu- Aβ interaction. This 
then leads to the oxidative stress toxicity observed in neuronal cell culture and the evidence 
presented prior that oxidative injury contributes to the pathology of AD [62, 63]. An opposing 
effect, however, is that Cu2+ has also been shown to prevent the amyloid fibril formation of Aβ by 
binding with Aβ, thus inhibiting the production of Aβ aggregates [64].  
Brain tissue contains the highest levels of Zn in the human body where it is substantially 
enriched in the glutamatergic nerve terminals [65, 66]. Upon neuronal activation it is released into 
the synaptic cleft and interacts with neuronal receptors, ion channels, and transmitters to regulate 
neuronal transmission [67-69]. It has been established that Zn is highly enriched in AD in Aβ 
plaques, potentially mislocalizing functional Zn from the rest of the brain [60, 70-72]. Zn can also 
bind Aβ via its histidine residues. This binding alters Aβ’s conformation and prevents its binding 
to Cu, inhibiting the H2O2 production that would result from Cu2+ reduction[62, 73]. High Zn 
concentrations are neurotoxic, however, so it is only in lower competitive concentrations that Zn 
binding protects against Aβ toxicity [74].  
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These studies indicate both protective and detrimental roles of Aβ, leading to questions 
about when and under what specific conditions it would serve these contradictory functions. 
1.3.3  APP cleavage products are necessary for normal function 
The “Amyloid hypothesis” focuses on the imbalance of production and clearance of Aβ1-42 
and its related peptides as the neurotoxic factors that contribute to gradual impaired neuronal 
function and cell death as seen in the progressive pathology of AD [75].  Numerous therapies and 
studies have focused on understanding both the physiological roles of APP and its cleavage 
products. They also focus on how the imbalance of these products may contribute to 
neurodegeneration in order to provide treatments that do not exacerbate the effects of depleting 
what could be a necessary and functioning protein. For example, APP knockout mice initially 
appear normal in early development, but eventually show reductions in body weight, grip strength, 
locomotor activity and synaptic transmission as well as sensitivity to epileptic seizures, forebrain 
defects, and a reduction in cerebral blood flow as a response to ischemia (restriction in blood 
supply) or hypoxia (oxygen deprivation) [76, 77]. Both APP and Aβ1-42 expression were found to 
be increased in hypoxic and ischemic conditions in the wild type, indicating a role for APP and its 
cleavage fragments in cerebral blood flow under specific conditions [77]. Experiments with mice 
over-expressing human APP show they have increased basal levels of DSBs and retain them 
longer after exploring novel environments, implicating a reduced capacity for repair [78]. A specific 
β-secretase (BACE-1) knockout mouse model shows no consistent phenotypic difference from 
wild type littermates, despite BACE being the primary β-secretase of APP and its knockout 
resulting in significantly less Aβ1-40 and Aβ1-42 production overall [79]. 
γ-secretase knockouts, however, are not conducive to AD studies as this enzyme is not 
specific to a single pathway. The γ-secretase complex cleaves numerous substrates including 
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APP and Notch. Specifically, the γ-secretase subunit PSEN1 is a key regulator of Notch and Wnt, 
and is essential for the developmental maturation of glia and neurons. Notch signaling itself is 
responsible for neuronal differentiation during embryogenesis and is also involved in neuronal 
plasticity [80, 81]. PSEN1 knockout mouse models exhibit perinatal lethality, skeletal 
deformations, intracranial hemorrhaging, and CNS abnormalities resembling Notch knockout 
phenotypes [82, 83]. PSEN2 knockout mice, however, only show a mild pulmonary phenotype, 
indicating the γ-secretase subunits PSEN1 and PSEN2 have non-identical functions in mice [84, 
85]. Numerous γ-secretase inhibitors have been tested that successfully reduce the amount of Aβ 
produced in mouse models and patients. These inhibitors specifically target the PSEN1 and 
PSEN2 subunits of γ-secretase. Due to off target effects and side effects, however, including 
those affecting Notch signaling, these γ-secretase inhibitors are not currently able to be used in 
clinical trials for use as AD therapeutics [86]. What these and future studies do provide is insight 
into the targets of the secretases, maintenance of homeostasis of Aβ, and how to modify 
treatments to target specific proteins in order to prevent the pathology of AD from developing. 
1.4 Oxidative stress in AD 
Oxidative stress is characterized by an imbalance in the production of ROS and manifests 
in high levels of oxidized proteins, advanced glycation end products, lipid peroxidation end 
products, and the formation of toxic species such as peroxides, alcohols, aldehydes, free 
carbonyls, ketones, cholestenone and oxidative modifications in nuclear and mitochondrial DNA. 
ROS are generated endogenously by cellular metabolism and by a variety of exogenous agents 
such as ionizing radiation. Metabolically-generated ROS can generate ~10,000 oxidative lesions 
in DNA per day [87].  Neurons also carry a large number of mitochondria which are the main 
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sources of ROS during glutamate excitotoxicity [88].  
Oxidative DNA lesions resulting from ROS can consist of single and double strand DNA 
breaks and oxidized base adducts such as 8-hydroxyguanosine (8-OHG). Studies have found 
both increased levels of 8-OHG in mitochondrial and nuclear DNA in the cortex of AD patients 
and increased levels of γ-H2AX, a modified histone and marker for DSBs, in the hippocampal 
region of AD patients [13, 89].  
Other markers for oxidation have been used to indicate oxidative stress in AD studies, 
including methionine, an essential amino acid [90]. In the case of Aβ1-42, which contains a 
methionine at residue 35, it is suggested that the interaction of the sulfur atom of Met-35 with Ile-
31 leads to an intermediate that can be oxidized by free oxygen to produce a sulfuramyl radical 
[91]. When introduced to rat embryonic primary hippocampal neurons, it induces oxidative 
damage evidenced by protein carbonyls and neurotoxicity. Vitamin E, a chain breaking 
antioxidant, modulates these effects [90]. When the sulfur in methionine is substituted with a 
methylene moiety to lead to a norleucine derivative (Aβ(1-42M35NLE), these peptide led to no 
oxidative damage, no neurotoxicity, and no free radical formation in 9-11 day murine primary 
hippocampal neurons [92]. In vivo studies utilizing transgenic Caenorhabditis elegans modified to 
produce human Aβ in their muscle wall further confirmed the importance of methionine in the 
oxidative and neurotoxic properties of Aβ1-42 as experimental organisms with Met35 substitutions 
displayed reduced Aβ aggregates and did not show progressive paralysis or slow growth observed 
in the wt Aβ strains  [93]. These studies support that Aβ1-42 itself induces oxidative stress and that 
antioxidant therapies may modulate its neurotoxic effects.   
More evidence of free radical induced oxidative stress in AD has been found in lipid 
peroxidation, protein oxidation, and DNA/RNA oxidation in AD patient brain samples. Altered 
indices of lipid peroxidation in AD brains include thiobarbituric acid reactive substances (TBARS), 
phospholipid composition, enzyme activity to clear lipid peroxidation products, isoprostane 
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concentrations, and concentrations of α- and β- unsaturated aldehydes [94, 95]. Thiobarbituric 
acid reacts with lipid peroxidation products, providing a means to measure oxidative stress. Levels 
of TBARS were found to be significantly increased in the hippocampal and pyriform cortex regions 
of AD patients compared to controls, indicating increased oxidative stress in AD patients [94]. 
Polyunsaturated fatty acids such as arachidonic acid and docosohexenoic acid are abundant in 
the brain and have been shown to be highly oxidizable. Studies on membrane phospholipids have 
indicated a decrease in levels of these specific phospholipids in AD, indicating high levels of 
oxidation activity [96].  
As mentioned in Chapter 1.3 redox recycling of Aβ produces hydrogen peroxide. This has 
been found to occur in the presence of biological reducing reagents with cholesterol and long-
chain fatty acids as the most likely reductants due to Aβ toxicity mostly associated with the 
membrane [97-99]. One β- unsaturated aldehyde, HNE (4-hydroxy-2-trans-noneal), is a major 
product of lipid peroxidation in the membrane, and concentrations of HNE have been shown to 
be increased in multiple brain regions, including the hippocampus, and in the ventricular 
cerebrospinal fluid (CSF) of AD patients [100]. HNE has also been implicated in Fe-induced 
oxidative damage in cholinergic neurons [100, 101]. These are the neurons primarily affected in 
the basal forebrain of advanced AD patients with a reduction in number of cholinergic neurons 
and decrease in choline acetyltransferase (ChAT) activity correlating with cognitive decline [102-
104].   
Studies have shown that oxidative stress induces the γ-secretase mediated expression of 
β-secretase, contributing to an increase in amyloidogenic Aβ production in AD pathology. In 
response to oxidative stress [e.g.-production of lipid peroxidation product 4-hydroxy-2,3 noneal 
(HNE)], γ-secretase cleavage of APP produces the ACID cleavage product which translocates to 
the nucleus and mediates transcriptional upregulation of BACE1 expression [105-107]. Some 
studies have found an increase in Aβ oligomers associated with an increase in DSBs in human 
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brain tissue, while others have found higher levels of oxidative damage associated with an 
increase in Aβ oligomers in human AD patients despite research claiming an anti-oxidative role 
of Aβ [13, 14, 105]. 
The oxidative modification of amino acid side chains and protein cross-linking can alter 
protein function and prevent malfunctioning proteins from being degraded by proteinases [108-
110]. Direct attacks on amino acid side chains by free radicals or the products of lipid peroxidation 
(e.g.-HNE) acting upon proteins can produce protein carbonyl groups which can be used as 
biomarkers of oxidative stress [111]. These can be detected via numerous fluorescent or 
immunochemical assays [108, 112]. Studies have consequently shown that protein carbonyl 
levels are increased in the frontal pole, hippocampus, and superior middle temporal gyrus in AD 
brains, correlating with AD histopathology [113-117].  
Together, these studies that utilize markers for evidence of oxidative stress including 
increased levels of 8-OHG, γ-H2AX, lipid peroxidation, DNA/RNA oxidation, and protein carbonyl 
groups imply a strong correlation between oxidative damage, Aβ, and AD neuropathology.  
1.5 DNA repair and genomic stability 
1.5.1  DNA repair mechanisms 
Many different types of DNA lesions can occur due to damage from endogenous and 
exogenous sources. The main pathways to repair DNA lesions are nucleotide excision repair 
(NER), base excision repair (BER), mismatch repair (MMR), single strand break repair (SSBR), 
and double strand break repair (DSBR) (Fig. 1-2). UV light and polycyclic aromatic hydrocarbons 
can directly damage DNA, leading to 6-4 photoproducts, bulky adducts, or cyclobutane pyrimidine 
dimers. The DNA strand containing the lesion is excised via NER. X-rays, ROS from oxidative 
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damage, and alkylating agents can cause abasic sites, oxidized, deaminated, and alkylated 
bases, and DNA single strand breaks (SSBs) which can be removed via BER or single strand 
annealing (SSA). In the BER pathway, specific glycosylases recognize and remove damaged 
nucleotide bases [118]. Ionizing radiation, UV light, and chemotherapy agents such as 
hydroxyurea can all lead to DSBs in the backbone of DNA. They can also occur due to SSBs in 
close proximity, or replication past previously existing lesions. DSBs are repaired via DSBR, either 
through single strand annealing (SSA), microhomology-mediated end joining (MMEJ), 
homologous recombination (HR), or non-homologous end joining (NHEJ). In SSA, homologous 
repeats are used to bridge DSB ends with RAD52 promoting the annealing of complementary 
ssDNA [119-121]. MMEJ promotes the use of 5-25 bp microhomologous sequences as broken 
DNA ends are aligned before ligation and does not rely on the NHEJ associated Ku70/80 complex 
proteins. This pathway often leads to significant deletions, insertions, translocations, inversions 
and rearrangements [122]. In NHEJ, the broken DNA ends are processed/digested and then 
directly ligated, potentially leading to nucleotide deletions and consequent frameshift mutations. 
Thus, NHEJ is considered error-prone [123]. HR utilizes undamaged templates in order to direct 
repair of the damaged strands. Replication and recombination errors can result in base 
mismatches, insertions and deletions. These erroneous nucleotides are excised via MMR 
independently of any specific glycosylases, unlike the BER pathway [124, 125].  
Maintaining the stability of the genome is essential for survival and overall health. Failure 
to efficiently and completely repair DNA lesions can lead to deleterious mutations, insertions and 
deletions, premature stop codons, and interrupted essential coding genes, the consequences of 
which can lead to cellular apoptosis or senescence and disease pathologies such as cancer or 
neurodegeneration [126-132]. Numerous studies have shown that deficiencies in BER, which is 
utilized primarily for the repair of DNA base modifications, play a large role in neurodegeneration. 
For example, the expression of DNA polymerase β, the polymerase that conducts gap-filling DNA 
synthesis, was reduced in AD patients [133]. Also, numerous mutations in BER proteins have 
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resulted in an increase in genomic mutation rates, implying that the reduction in efficient repair 
could lead to genomic instability, cancer, and neurodegenerative pathologies [134]. Mutations in 
genes required for efficient repair of SSBs or DSBs can also lead to numerous neurodegenerative 
diseases such as Cockayne syndrome (CS), Xeroderma pigmentosum (XP), and Ataxia 
telangiectasia (A-T) [135].  Studies have also found high levels of oxidized DNA bases such as 
8-oxoG in nuclear and mitochondrial DNA in the brains of Mild Cognitive Impairment (MCI) 
patients who are in the phase between normal aging and early dementia [136]. 
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Figure 1-2 Representation of DNA repair pathways. 
A. Endogenous and exogenous sources of DNA damage. B. Types of DNA lesions resulting from damage. 
C. DNA repair pathways utilized for repair of specific DNA lesions. 
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1.5.2  Homologous Recombination (HR) 
DSB are the most deleterious forms of DNA damage. While NHEJ tends to be more error 
prone and HR more error free, there are numerous factors that influence DSB repair pathway 
choice. These factors include the cell cycle phase and the initial resectioning process [137]. The 
result after damage is the initiation of cell cycle arrest and repair either via HR or NHEJ followed 
by the re-initiation of the cell cycle or, failing sufficient repair, apoptosis or senescence.  
For more error-free repair of DSBs, canonical HR can occur during the late S & G2/M 
phases of the cell cycle when an intact sister chromatid is present and in close proximity of the 
break & can be utilized as a template (Fig. 1-3) [138]. This pathway first involves resection, or 
degradation of the broken DNA ends, into single stranded DNA tails with 3’ overhangs by the 
MRN complex of nucleases (MRE11, RAD50, NBS1) and its co-factor Sae2. Once the MRN 
complex binds to the DSB ends, the endonuclease CtIP interacts with the complex and initiates 
resectioning in the 5’ to 3’ direction, generating 3’-OH single-stranded DNA (ssDNA) overhangs. 
The ssDNA generated is immediately coated by the ssDNA binding protein replication protein A 
(RPA) to prevent degradation or direct ligation [139].  
RAD51 filament formation, which is essential for HR recombination, occurs following RPA 
coating. However, RPA directly blocks RAD51 binding to ssDNA. In human cells, BRCA1 recruits 
PALB2 (Partner and Localizer of BRCA2) and BRCA2 to assist in loading RAD51 onto the DNA 
[140]. This is another step where pathway choice can be mediated. Here, ubiquitylation of key 
residues of PALB2 by the E3 ligase complex CRL3-KEAP1 in the G1 phase of the cell cycle 
prevents BRCA1 binding, thus favoring NHEJ instead in the G1 phase. CRL3-KEAP1 is 
downregulated in the S phase when the deubiquitinase USP11 is upregulated, thus favoring HR 
in the S phase [141]. ATR activation at the resected DSB also leads to the phosphorylation of S59 
in PALB2, enhancing its complex formation with BRCA1 and further favoring HR [142]. 
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After BRCA1 recruits PALB2 and BRCA2, BRCA2 assists in loading RAD51 recombinase 
onto the 3’ DNA overhangs to form nucleoprotein filaments, displacing RPA. In yeast cells, Rad52 
is essential for Rad51 filament formation in vivo. This is not the case in human cells as RAD52’s 
role in canonical HR is not clearly defined [143, 144]. However, in BRCA2 deficient cells, RAD52 
becomes essential for RAD51 filament formation [145]. In vertebrates, there are five different 
RAD51 paralogs (RAD51B, RAD51C, RAD51D, XRCC2, XRCC3), each necessary for RAD51 
foci formation after damage, and each playing different roles in filament formation that are still 
being investigated [146]. These RAD51 paralogs each load into the RAD51 filament in a varying 
arrangement, the purpose of which isn’t entirely known. It is speculated, however, that their 
arrangement helps protect the ssDNA from nuclease activity as Rad55 and Rad57 in yeast form 
a heterodimer that blocks Srs2 helicase activity intended to prevent hyper-recombination [147].   
These RAD51 filaments then search for a homologous DNA template on the sister 
chromatid and form a joint heteroduplex molecule between the damaged DNA and undamaged 
template. RAD54 associates with the RAD51-ssDNA filaments and stabilizes them independently 
of its ATPase activity [148]. The 3’ end of the invading DNA strand must then intertwine with the 
donor complement strand to form a primer-template junction competent for DNA synthesis. This 
is known as the D-loop. Minimally, only the 3’ end is required to form a primer-template junction, 
however it can be hundreds of base pairs long. As evidenced by studies using substrates with 
terminal heterologies, the junction forming sequence need not be directly located at the 3’ end 
[149].  
DNA synthesis begins at the D-loop, involving Pol δ, PCNA, and its loader RFC1-5, 
followed by disengagement of the invading strand [150]. The resulting ssDNA strands are then 
immediately bound by RPA. The DNA ends can now anneal within the region of homology created 
within the D-loop. However, how this annealing process occurs is largely unknown. In yeast, 
Rad52 fulfills this role [151]. In humans, RAD52 is capable of annealing homologous RPA-coated 
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ssDNA strands such as in the SSA pathway [119, 121]. However, there are no studies that 
currently clearly define its role in HR.  
If annealing does not occur, the formation of double Holliday junctions (dHJ) may proceed. 
In forming the dHJ, the second resected DSB end may anneal to the D-loop, or both DSB ends 
instead invade the donor and proceed onto DNA synthesis. When the dHJ is processed, it will 
result in either non-crossover or crossover products. Due to crossover products (as high as 50%), 
somatic cells largely avoid the formation of dHJ, and prefer resolution of HR via annealing, also 
known as synthesis-dependent strand annealing (SDSA) [152].  
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Figure 1-3 Simplified representation of Homologous Recombination (HR) repair pathway. 
A. After DSB formation, resection occurs to form 3’ ssDNA overhangs. After successful homology search, 
strand invasion occurs to form a D-loop structure, followed by DNA synthesis. B. In SDSA, only non-
crossover products are formed after the D-loop unwinds and the freed ssDNA anneals with the 
complementary ssDNA on the other end. C. Alternately, the second DSB end can be captured to form an 
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intermediate, resulting in noncrossover or crossover products after resolution of two Holliday junctions 
(HJ)s. 
 
1.5.3  Non-homologous end joining (NHEJ) 
For more error-prone resolution of DSBs, the NHEJ pathway can be used throughout the 
cell cycle (Fig 1-4) [153]. In studies using human fibroblasts, NHEJ was found to repair nearly all 
DSBs outside of the G2/S cell cycle phases, as well as almost 80% of DSBs within the G2/S 
phases not proximal to replication forks [154]. It has been proposed that preference for NHEJ 
repair is largely due to a high abundance of Ku protein, one of the first proteins recruited to broken 
DNA ends, which promotes NHEJ and also inhibits the DNA resectioning event that leads to HR 
[155, 156]. 53BP1 has also been identified as a negative regulator of HR, promoting NHEJ 
instead. It limits the resection process by binding to specific histone modifications around the 
break site. The Tudor domain of 53BP1 binds to H4K20Me2, a histone modification present 
throughout the genome, while its “Ubiquitin-Dependent Recruitment” region binds to H2AK15ub, 
a histone modification induced by RNF168 after DNA damage signaling at the DSB [157, 158]. 
This negative regulation of HR by 53BP1 is counteracted by BRCA1, which allows resection to 
continue in the presence of 53BP1. 53BP1 binding is also influenced by multiple factors, thus 
affecting its ability to direct DSB repair pathway choice. These factors include proteins that 
compete for H4K20Me2 binding sites such as JMJD2A and L3MBTL1, or the histone 
acetyltransferase complex TIP60 [159, 160]. TIP60 also creates a chromatin environment more 
favorable to BRCA1 binding than 53BP1 by acetylating H4K16 to H4K16ac, interfering with the 
binding between 53BP1’s Tudor domain and histone H4 [161, 162]. 53BP1 also has reduced 
binding during S phase due to a lessening of H4K20Me2 modifications during DNA replication, 
driving DSB repair towards HR [163].     
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Nuclease activity occurs first at the two incompatible broken DNA ends involved in a DSB. 
The resectioning process in NHEJ occurs by the recruitment of DNA-PKcs with the endonuclease 
Artemis. In NHEJ, the Ku heterodimer consisting of Ku70 and Ku80 is first recruited to the damage 
site. This complex acts as a scaffold for DNA-PKcs as DNA-PKcs interact with the C-terminus of 
Ku80. Although the last 12 amino acids of Ku80 are sufficient for this interaction, Ku80 must be 
bound to a DNA end in order to form a strong complex with DNA-PKcs [164-166]. Following 
binding to DNA, the DNA-PKcs autophosphorylate and activate Artemis. This is accomplished by 
the phosphorylated DNA-PKcs phosphorylating the C-terminal inhibitory region of Artemis, 
dissociating it from the N-terminal catalytic domain [167]. When in complex with DNA-PKcs, 
activated Artemis has endonuclease activity on the 5’ and 3’ overhangs [168, 169]. Numerous 
members of the polymerase X family of polymerases then participate in DSB repair by NHEJ. 
These polymerases, such as Pol µ and Pol λ have an N-terminal BRCA1 C terminus (BRCT) 
domain that allows them to interact with the Ku complex [167]. These polymerases incorporate 
nucleotides during NHEJ, but in a template independent manner [170, 171]. In a complex with X-
ray repair cross-complementing 4 (XRCC4) protein, DNA ligase IV (Lig4) then ligates the two 
DNA ends together [172]. The result of NHEJ is not a perfect joining of the two broken DNA ends 
as Artemis activity can lead to nucleotide loss and polymerase activity can lead to nucleotide gain 
[173]. These final results can promote frameshift mutations, interrupted essential genes, and 
premature stop codons, all of which compromise genomic fidelity. 
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Figure 1-4 Simplified representation of Non-homologous end joining (NHEJ) repair pathway. 
The broken DNA ends are processed and directly ligated by actions of the end-binding Ku70/80 complex 
and DNA-PKcs, followed by Artemis end processing and XRCC4 and DNA ligase IV. 
1.5.4  Transcription-coupled homologous recombination (TC-HR) 
It has long been assumed that HR can only take place during the late S/G2 phases of the 
cell cycle where sister chromatids are present as templates [174]. Except for in the hippocampus 
and striatum, most neurons in the adult human brain are terminally differentiated and non-dividing, 
and therefore are assumed to be incapable of utilizing HR for DSB repair [175, 176]. For post-
mitotic cells such as terminally differentiated neurons that cannot utilize a sister chromatid 
template, only the error-prone NHEJ pathway has been proposed [123]. However, recent studies 
in the Lan lab have elucidated an RNA-templated HR repair mechanism of DSBs at active 
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transcription sites during the G0/G1 phase called transcription-coupled homologous recombination 
(TC-HR) [177].  
Cockayne syndrome B (CSB) protein is involved in the transcription-coupled NER (TC-
NER) pathway. After DNA damage induced by UV light, RNA polymerase II (RNA POLII) stalls at 
bulky lesions and CSB is recruited to facilitate NER directed repair of the transcribed DNA strand 
[178, 179]. Due to the fact that patients with CSB deficiencies also manifest neurodegenerative 
pathologies and CSB-defective cells are sensitive to IR, it was hypothesized that CSB must play 
a larger role in maintaining genomic stability against other forms of DNA damage, specifically 
DSBs, the more deleterious form of damage [180-183]. The Lan lab therefore investigated the 
role of CSB in DSB repair using the DNA damage at active transcription sites (DART) system 
(Fig. 1-5A-D), which enables the study of molecular responses to light-induced DNA damage at 
single genomic loci with controllable transcription [184, 185]. In the DART system, when activated 
by visible light (550-580 nm), the modified red fluorescent protein chromophore KillerRed (KR) 
emits site-specific ROS [186, 187] (Fig. 1-5A). When positioned directly onto DNA, KR can induce 
oxidative damage and DNA strand breaks after white fluorescent light excitation. In order to 
localize KR, a tandem tetracycline repressive element (TRE) array cassette of approximately 200 
copies of 96 random TRE repeats was integrated at a defined genomic locus in U2OS TRE cells. 
This specific locus has been determined as adjacent to the centromere of the X chromosome in 
a heterochromatinized region, or region with condensed chromatin. A CMV promoter is located 
after the TRE repeats to allow the activation of transcription upon transient expression of TRE-
fusion proteins, specifically those fused to the transcription activator VP16 (TA) (Fig. 1-5B). U2OS 
TRE cells are exposed to white light for 15 min, and the tet-repressor (tetR)- or tet-transcription 
activator (TA)-tagged KR proteins (tetR-KR or TA-KR) induce similar amounts of ROS-induced 
DSBs at transcriptionally inactive or active sites, respectively in real time [184] (Fig. 1-5C&D). 
 27 
 
Figure 1-5. Schematic for the DNA damage at active transcription sites (DART) system for targeted 
single cell nuclei DNA damage. 
A. KillerRed (KR) induced by white or green light (550-580nm) produces ROS. B. A tandem tetracycline 
repressive element (TRE) array cassette integrated at a defined genomic locus in U2OS-TRE cells allows 
fusion proteins to translocate to a specific location for DNA damage induction. A CMV promoter is located 
after the TRE repeats to allow the activation of transcription upon transient expression of transcription 
activator (VP16) containing proteins. C. Scheme of the experimental system and senerios of TA-KR/cherry 
and tetR-KR/cherry in U2OS TRE cells where cherry is the non-ROS producing control. D. Confocal image 
of single U2OS-TRE nucleus with TA-KR (red), DSB marker γ-H2AX (blue), and DSB repair protein 53BP1 
(green) after light induction to illustrate DNA damage. Adapted from [177] with permission from the 
publisher. 
 
 28 
Using the DART system, the Lan lab demonstrated that HR proteins RAD52, RAD51, 
RAD51C, and RPA1 are enriched at transcriptionally active DNA damage sites in cells 
synchronized in the G0/G1 phase. This recruitment is dependent upon CSB repair protein (Fig. 1-
6). They also found that RAD52 and RAD51C interact with CSB independently of DNA after 
damage, but this interaction is abolished with transcription inhibition. The C-terminus of RAD52 
co-localizes to actively transcribed DNA damage sites [177]. These data imply that RAD52 foci at 
actively transcribed DNA damage sites require the presence of an RNA template. This messenger 
RNA (mRNA) may be utilized as a bridge or template for the recombination process for error-free 
break repair in TC-HR [188-190]. Finally, inhibition of transcription sensitizes wild type cells to IR, 
but not CSB-deficient cells. This indicates that CSB facilitates transcription-coupled 
recombination to enable cell survival [177].   
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Figure 1-6. Model of CSB dependent RNA templated repair at transcriptionally activated DNA 
damage sites. 
RNA polymerase II stalls at actively transcribed DNA damage sites containing DSBs, followed by 
recruitment of CSB, RAD52 and RAD51C, RAD51 and RPA. After repair, CSB is polyubiquitinated, followed 
by the release of remaining repair factors and RNA polymerase II phosphorylation to resume transcription. 
 
An RNA-templated, RAD52 directed mechanism of HR has also been reported in yeast 
[191]. Prior to my research, however, it was not known whether this transcription dependent HR 
pathway existed in neurons or other post-mitotic cells.  
R-loops are three stranded nucleic acid structures formed during the transcription process. 
They are composed of a nascent RNA strand hybridized with the DNA template and the single 
stranded non-template DNA strand. They are formed by RNA polymerase II transcribing a C-rich 
template so that a G-rich transcript is generated and depend on three main features: high G 
density, negative supercoiling, and DNA nicks [192-194]. It’s been hypothesized that the formation 
of R-loops can lead to genomic instability. The precise mechanisms for this are still under 
investigation, but models have been proposed showing that the exposure of ssDNA during the 
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RNA/DNA hybrid formation would leave the ssDNA strand susceptible to DNA lesions [195]. Also, 
the unpaired strand may be susceptible to DNA damage from deamination of dC to dU, leading 
to DSBs [196-198]. Unpublished research in the Lan lab using the DART system and antibodies 
for anti-S9.6, which is an antibody specific for RNA/DNA hybrids, has also shown that oxidative 
stress induces the formation of R-loops. TC-HR repair factors RAD52 and RAD51 have been 
shown to co-localize with R-loops at actively transcribed damage sites as compared to I-SceI 
endonuclease cleavage sites. (Of note, the I-SceI endonuclease recognizes a specific 18bp 
sequence and leaves a 4bp 5’ overhang, but does not induce or require transcriptional activity 
[199].)  
1.6 Therapies and treatments 
Current treatments for AD cannot slow or stop the neuronal death or synaptic loss seen in 
AD pathology, nor have they been able to sufficiently prevent toxic Aβ1-42 oligomers from incurring 
AD associated damage to neurons. Many therapies focus instead on alleviating symptoms 
through increasing neurotransmitter levels. There are five such treatments currently available, 
which are rivastigmine, galantamine, donepezil, memantine, and memantine combined with 
donepezil. Rivastigmine, galantamine, and donepezil are acetylcholinesterase inhibitors. 
Synthesis of the neurotransmitter acetylcholine (ACh) takes place in the cytoplasm of cholinergic 
neurons via synthesis from choline and acetyl-coenzyme-A by the enzyme choline 
acetyltransferase (ChAT) [200]. During neurotransmission, ACh is released from a nerve into the 
synaptic cleft where it binds to ACh receptors on the post-synaptic membrane and relays a signal 
from the nerve. Acetylcholinesterase terminates this signal by hydrolyzing ACh [201].  Cholinergic 
neurons innervate almost all regions of the human brain. They are involved in critical processes 
such as waking and sleep, memory formation, learning, stress response, and sensory information 
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[202]. In AD, one notable change in the human brain is a significant reduction in cholinergic 
neurons. Cholinergic neuronal loss and consequent deficits in cholinergic transmission have been 
shown to impair cortical and hippocampal information processing, decision-making processes, 
and changes in hippocampal synaptic transmission which correlate with memory loss [203-208]. 
The use of acetylcholinesterase inhibitors has been shown to temporarily improve symptoms in 
AD patients by increasing availability of the neurotransmitter ACh, but the effectiveness of the 
drugs is patient specific and limited in duration [1].   
There are over 112 agents being tested for use as treatment for AD in 2018. These include 
26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in 
phase I. 63% of these are disease modifying therapies (DMTs) intended to prevent or delay the 
onset of AD or slow its progression, 22% are symptomatic cognitive enhancers, 12% are 
symptomatic agents addressing neuropsychiatric and behavioral changes, and 3% have 
undisclosed methods of action (MOAs). The majority of individuals involved in these studies 
include cognitively normal patients with evidence of amyloid pathology (analyzed by cerebrospinal 
fluid-CSF measures or amyloid positron emission tomography-PET) or individuals with genetic 
profiles placing them at high risk for developing AD, patients with prodromal AD/mild cognitive 
impairment (MCI), and patients with mild-moderate AD [209].  
There are very few agents currently being tested that target the moderate to advanced 
stages of AD. The reason for this is the lack of surrogate markers, or measures of disease that 
can be used for a clinical endpoint. There are also very few biomarkers in AD. The most common 
ones used in the 2018 clinical trials were CSF amyloid, CSF tau, volumetric magnetic resonance 
imaging (MRI), and amyloid PET [209]. This dearth of biomarkers has led to a misdiagnosis rate 
of upwards of 20% in previous AD clinical trials. This can contribute significantly to trial failures 
[210]. What is important to consider is that these trials are increasingly using preclinical and 
prodromal populations, reflecting current research findings that indicate AD pathology develops 
much earlier than when patients manifest the disease symptoms. 
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1.7 Summary 
Although a great amount of research has been conducted on AD, little progress has been 
made on the actual treatment of the disease. This is mainly due to the elusive nature of the 
disease’s causal factors. Although the amyloid hypothesis can explain the pathology and 
progression of AD, it does not explain what leads to the initial events that trigger overproduction 
and accumulation of toxic Aβ, nor how it affects distinct cellular processes. 
The data acquired in this thesis implies that although the TC-HR pathway provides the 
means for post-mitotic cells (and cells in the G0/G1 phase of the cell cycle) to maintain genomic 
stability over the more error-prone NHEJ DSB repair pathway, the process of active transcription 
and R-loop formation itself can predispose these neuronal cells to detrimental DNA damage when 
exposed to endogenous cellular products like Aβ1-42. This thesis also provides insight into how Aβ 
contributes to the downregulation of essential repair proteins and their DNA damage response in 
the TC-HR pathway, pointing to a mechanism of Aβ and the dysregulation of DNA damage repair 
in the development of AD. 
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2.0 Materials and Methods 
Cell cultures and transfection 
U2OS osteocarcinoma cells and U2OS-TRE osteocarcinoma stable cells containing a 
tandem tetracycline repressive element (TRE) array cassette were cultured in high-glucose 
Dulbecco’s modified Eagle’s medium (DMEM) with 10% (vol/vol) fetal bovine serum (FBS) at 
37°C, 5% CO2. U2OS-TRE cell line for the DART system has been described in previous literature 
[177]. DR-GFP and Ej5-GFP stable cells were cultured in Dulbecco’s modified Eagle’s medium 
with 4.5 g/L glucose and L-glutamine without sodium pyruvate with 10% (vol/vol) FBS and 0.1X 
GlutaMAX (Gibco) at 37°C, 5% CO2. Primary neuronal cultures were prepared as previously 
described [211] with minor modifications. Rat cortical tissues were dissected from E17 Sprague 
Dawley rat brains. For the first 48 hr, brain cultures were maintained in MEM (Life Technologies) 
containing 2% heat-inactivated fetal bovine serum (Cellgro), 2% heat-inactivated horse serum 
(Life Technologies), 1 g/L glucose (Sigma), 2 mM Glutamax (Life Technologies), 1 mM sodium 
pyruvate (Cellgro), 100 μM non-essential amino acids (Cellgro), 50 U/mL penicillin and 50 μg/mL 
streptomycin (Corning). The culture medium was then changed to 0.5 mL/well of fresh serum-free 
Neurobasal medium containing 2% B27 supplement (Life Technologies), 2 mM Glutamax I (Life 
Technologies), 0.5 mg/mL albumax I (Life Technologies) and penicillin-streptomycin 
(Corning). Primary neurons were plated at 1.0 × 105 on 3.5 cm glass bottom culture PDL (0.1 
mg/mL) coated dishes (MatTek) or on 12mm glass coverslips coated with poly-D-lysine (Millipore) 
in 6-well plates.  
Neuronal cells were treated or transfected at DIV12-14. For transfection, Neurobasal 
media was removed and saved in 37°C, 5% CO2, and 1 mL pre-warmed transfection media was 
added (1XMEM w/o bicarb [11430-030, Invitrogen], 2XGlutamax [35050-061, Invitrogen], 0.02 M 
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Hepes [H30237.01, Thermo Fisher], 1 mM NaPyruvate [11360-070, Invitrogen], and 0.033 M filter 
sterilized glucose [G5400, Sigma]). Transfected neurons were incubated at 37°C, 0% CO2 for 1.5 
hr, then transfection media was removed and replaced with warmed saved Neurobasal media. 
All U2OS cells were transfected using Lipofectamine 2000 (Invitrogen) and Opti-MEM 
(Gibco). All neurons were transfected using 1 mL transfection media, 500 µL OptiMEM, 5 µL 
Lipofectamine2000, and 4 µg total DNA per 3.5 cm MatTek glass-bottom dish 
 
Plasmids 
pBROAD3/TA-KR, tetR-KR, TA-Cherry, tetR-Cherry, pCMV-NLS-I-SceI, pEGFP-RAD52 
[177], pEGFP-Ku70, pEGFP-XRCC1, and pEGFP-BRCA1 [212] are described in previous 
literature. 
 
Polymerase II inhibitors  
RNA polymerase II inhibitors 5,6-Dichlorobenzimidazole 1-β-d-ribofuranoside (DRB; 
D1916, Sigma) was added with a final concentration of 40 µM for 24 hr, or α-amanitin (A2263, 
Sigma) at 100 µg/mL for 15 min before laser microirradiation.  
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test. *p<0.05, **p<0.01, ***p<<0.01. 
 
RNase H treatment  
Previously transfected 80% confluent U2OS cells and neurons in 3.5cm glass bottom 
dishes (MatTek) were rinsed once with 1XPBS and incubated with 1xRNase H buffer with/without 
RNase H (EN0201, Thermo Scientific) at room temperature (RT) for 15 min. Cells were treated 
with 0.1 mM 8-MOP and incubated for 10 min at 37°C followed by confocal microscopy and laser 
microirradiation. 
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The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test. *p<0.05, **p<0.01, ***p<<0.01. 
 
Immunofluorescent staining (IF) 
For staining, 80-100% confluent neurons and U2OS cells in a 3.5 cm dish were washed 
with 1XPBS three times and fixed with 3.7% paraformaldehyde (Affymetrix, 19943 1 LT) for 15 
min at RT. The fixed cells were rinsed three times with 1XPBS, then permeabilized with 0.2% 
Triton X-100 for 10 min at room temperature, then rinsed three times with 1XPBS. They were 
optionally blocked by 5% BSA (SIGMA, A-7030) in 0.1% PBS-Tween (PBST) for 1 hr at room 
temperature. Primary antibodies were diluted in 0.1% PBST and 5% BSA and incubated with cells 
overnight in 4°C. Cells were then washed three times with 0.05% PBST and incubated with 
secondary antibody Alexa Fluor 488 goat anti-mouse immunoglobulin G and Alexa Fluor 594 goat 
anti-rabbit immunoglobulin G conjugate; or Alexa Fluor 488 goat anti-rabbit immunoglobulin G 
conjugate, Alexa Fluor 594 goat anti-mouse immunoglobulin G conjugate, and Alexa Fluor 405 
goat anti-mouse immunoglobulin G conjugate (Invitrogen) for 1 hr at room temperature. Cells 
were washed three times with 0.05% PBST and once with 1XPBS. For optional DAPI staining of 
the nuclei, cells were treated with 1:1000 DAPI for 5 min, washed three times in 1XPBS. Cells 
were then washed once with DI water, dried, then kept in 1XPBS and imaged using an Olympus 
FV1000 confocal microscopy system (Cat. F10PRDMYR-1, Olympus). Primary antibodies used 
in this research were anti-γH2AX ser139 (1:2000, JBW301, Millipore), anti-MAP2 (1:1000, 
MAB378, Millipore), anti-BrdU (IIB5) (I1212, Santa Cruz), anti-phospho-histone H3 (Ser10) 
(1:100, PA5-17869, Invitrogen),  
FV1000 software was used for acquisition of images. For quantification of relative foci 
intensity at KR sites, the intensity of foci and background was acquired by ImageJ 1.50i software, 
and the fold increase of foci is calculated as the foci intensity divided by background intensity 
(n=10). For quantification of the percentage of foci positive cells, 100 cells were counted in every 
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experiment (n=3), and representative data are shown. For quantification of γ-H2AX foci frequency 
after IR, the cells with more than 20 γ-H2AX foci were counted and divided by the total cell 
number.  
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test or two-way ANOVA and Tukey’s multiple comparisons 
test. *p<0.05, **p<0.01, ***p<<0.01. 
 
Immunostaining of R-loops (anti-S9.6 antibody) 
For S9.6 staining, U2OS-TRE cells were fixed and permeabilized in a 3.5 cm glass-bottom 
dish using standard protocol with 4% paraformaldahyde, then incubated in TE buffer (10 mM Tris-
HCl, 2 mM EDTA, pH=9) and steamed on a 95°C heating block for 20 min to expose the antigen. 
Then the dish was allowed to cool and washed 3 times with 1XPBS. The cells were then blocked 
using 5% BSA in 0.1% PBST for 0.5 h at room temperature. The first antibody S9.6 (ENH001, 
Kerafast) and secondary antibody were diluted in 5% BSA in 0.1% PBST and the standard IF 
protocol was followed. This protocol was modified from the classical heat-induced antigen 
retrieval method for paraformaldehyde-fixed tissues using Tris-EDTA buffer [213].   
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by two-way ANOVA and Tukey’s multiple comparisons test. *p<0.05, **p<0.01, 
***p<<0.01. 
 
Microscopy and laser light irradiation  
Prior to laser irradiation, except for GFP-XRCC1 transfected cells, live cells were treated 
with 0.1 mM 8-MOP in Opti-MEM medium (Gibco) in glass bottom dishes and incubated for 10 
min at 37°C.  
Fluorescent images were obtained and processed with an FV-500 confocal scanning laser 
microscopy system (Olympus). U2OS and neuronal cells were placed on a temperature-controlled 
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(37°C) plate. A 405-nm scan laser system (Olympus) for irradiation of cells in the epifluorescence 
path of the microscope system was used. One scan of the laser light at full power delivers 
approximately 1,600 nW. We scanned cells 100-500 times with the 405-nm laser at full power 
focused through a 40x objective lens, which has been shown to induce SSBs and DSBs. The 
fluorescence intensity at an irradiated site was initially measured with a laser power/energy 
monitor (Orion; Ophir Optronics, Israel). The fold increase in fluorescence intensity of each site 
was quantified by measuring fluorescent intensity after damage induction/background nuclear 
intensity using ImageJ software (Fig 2-1) [212, 214, 215].  
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test. *p<0.05, **p<0.01, ***p<<0.01. 
 
Figure 2-1 Model of laser microirradiation. 
A. 405nm laser induces DNA DSB breaks in single cell nuclei allowing for real time visualization of GFP-
tagged repair protein recruitment to DNA damage sites. B. For quantification, fluorescence intensity of (a) 
GFP-tagged repair protein after DNA damage induction is compared to the (b) background intensity.  
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Protein expression and purification 
6xHis-tagged human RAD52 was expressed in E. coli Rosetta cells and purified as 
previously described [216]. 
 
Electrophoretic mobility shift assay 
RAD52 protein was serial diluted to indicated concentration and mixed with 10 nM 32P 
labeled ssDNA, ssRNA, dsDNA, dsRNA, RNA:DNA, or R-loop substrate in EMSA buffer (15 mM 
HEPES PH7.5, 1 mM MgCl2, 2% glycerol, 0.2 ug/ul BSA, 100 mM KCl, RNaseOut 0.16 U/𝝻𝝻l). The 
reaction mixtures were incubated at 37°C for 10min. After addition of gel loading buffer (50% 
glycerol, 20 mM Tris-HCl, pH 7.4, 0.5 mM EDTA, 0.05% orange G), the reaction mixtures were 
resolved by 5% native polyacrylamide gel electrophoresis in 1 × TBE buffer (90 mM Tris-borate, 
pH 8.0, 2 mM EDTA) at 4°C. The gels were dried, and the products were visualized by 
Phosphorimager. 
 
BrdU incorporation  
U2OS or neurons previously transfected with GFP-XRCC1 were treated with and without 
40 µM DRB and incubated at 37°C for 24 hr. Cells were then treated with laser microirradiation in 
sterile manner (lid not removed), then 0.01 mM BrdU was added and cells incubated at 37°C for 
24 hr. Cells were rinsed with 1XPBS, fixed with 3.7% paraformaldehyde for 15 min at room 
temperature, rinsed three times with 1XPBS, then treated with 2.5N HCl for 30 min at 37°C. Cells 
were rinsed three times with PBS, permeabilized with 0.2% Triton for 5 min at room temperature, 
then rinsed three times with PBS. Immunofluorescent staining proceeded as above. 
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test. *p<0.05, **p<0.01, ***p<<0.01. 
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Lysates and western blot 
Neurons seeded on a 24 well plate (3 wells per treatment) or 6 well plate (1 well per 
treatment), and U2OS cells seeded on 6 cm dishes were treated as indicated per each 
experiment. Cell lysates were prepared with 25-150 µL of lysis buffer per well (62.5 mM Tris pH 
6.8, 5% glycerol, 2% SDS, 0.1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride). Cells were 
scraped and pipetted into 1.5mL tubes, then allowed to sit on ice for 10 min. Samples were heated 
at 95°C and spun in a microcentrifuge at 10,000 rpm for 10 min, then the supernatant transferred 
to a new tube and the pellet discarded. Samples were run on 8%-12% SDS-polyacrylamide gels 
or 4-20% gradient gel (Mini-Protean TGX, 4561096), transferred to either PVDF or nitrocellulose 
membrane. For some transfers, the BioRad Trans-Blot Turbo system was used. The membranes 
were blocked in 5% non-fat milk with TBST for 1 hr before being incubated with primary antibody 
in 0.1% TBST and 5% non-fat milk overnight at 4°C. Primary antibodies used were anti-RAD52 
antibody (K1512, Santa Cruz), anti-BRCA1 (D-9, sc-6954, Santa Cruz Biotechnology), and anti-
γ-H2AX (ab12267, Abcam).  (Samples for probing with anti- γ-H2AX were not pre-treated with 
benzonase nuclease.) 
After primary antibody, membranes were washed with 0.1% TBST three times and 
incubated with secondary antibody in 0.1% TBST and 5% non-fat milk for 1 hr at room 
temperature. The membranes were washes three times with TBST and once with TBS before 
exposure using chemiluminescent HRP substrate (Millipore Catalog#: WBKLS0500). Secondary 
antibodies used were anti-β-Actin (A5441, Sigma Aldrich), anti-tubulin (ab6046, Abcam), and anti-
GAPDH (G9545, Sigma Adrich). 
Images were acquired in a BIO-RAD Universal Hood II machine or ChemiDoc Touch 
Imaging System (software version 2.3.0.07) and quantified with ImageLab software. All protein 
concentrations were normalized to loading controls before comparison to experimental controls.  
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The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test or two-way ANOVA and Tukey’s multiple comparisons 
test. *p<0.05, **p<0.01, ***p<<0.01. 
 
Aβ1-42 oligomer preparation  
Recombinant Aβ1-42 oligomers were prepared from lyophilized monomers treated with 
HFIP (A-1163-2, rPeptide) as described [13, 217]. 0.5mg of peptide was dissolved in 22uL fresh 
DMSO, then further diluted in 978uL ice cold Neurobasal media or 1XPBS to make 0.5mg/mL 
(100uM) solution. Solution was spun at 5000rpm 5 min 4°C and supernatant removed and kept. 
Peptide solution was incubated at 4°C overnight to oligomerize the amyloid beta. Then the 
solution was spun 5000rpm 5 min 4°C and supernatant removed. Aliquots were flash frozen in 
dry ice and kept at -80°C. Once thawed they were not re-frozen. Control samples were made 
using 22uL DMSO in 978uL Neurobasal media or 1XPBS.  
Protein concentration was measured using reverse phase HPLC and Pierce BCA Protein 
Assay Kit (Thermo Scientific). The ratio of monomers vs oligomers was determined using size 
exclusion chromatography on a 24 hr incubated sample. We also investigated the pelleted and 
supernatant fraction and observed the supernatant fraction was the toxic fraction, and DMSO did 
not induce the resultant effects. Additionally, we investigated Aβ1-42 oligomers via western blot by 
running diluted fractions with monomeric controls on 4-20% gradient gel (Mini-Protean TGX, 
4561096) (Fig. 5-3). After transferring the protein to nitrocellulose membrane, the membrane was 
boiled in a microwave for 5 min in 1XPBS, blocked with 5% non-fat milk for 1 hr, and probed with 
anti-6E10 antibody (BioLegend, 803004) according to western blot protocol described previously.  
 
Transmission Electron Microscopy (TEM) 
Transmission electronic microscopy was used to detect the presence of Aβ1-42 oligomers 
(Fig. 5-2B). Aβ1-42 sample (5 μL) was placed on a formvar grid and allowed to partly dry at room 
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temperature (RT). It was washed by touching it 3X to the surface of a drop of distilled water, and 
excess water removed by touching the grid to filter paper. Then, a small drop of 1-3% uranyl 
acetate in distilled deionized water was added to the grid. After 10 sec excess stain was removed 
by touching the edge to filter paper. The grid allowed to air dry at RT before examination using a 
transmission electron microscope (Jeol JEM 1400, Tokyo, Japan) imaged at 80 kV with the 
MegaView III Soft Imaging System (SIS).  
 
HR and NHEJ assays  
DR-GFP and Ej5-GFP stable cells were passaged onto 6-well plates and incubated in 
DMEM with 10% FBS until 60% confluent. Cells were transfected with pCMV-I-SceI plasmid using 
Lipofectamine 2000 (Life Technologies) for 48 hr and kept in the dark. 1 µM Aβ1-42 or Aβ control 
media was added for 5 hr. Then cells were spun at 600 rpm and washed with 1xPBS three times. 
Cells were analyzed by fluorescence activated cell sorting (FACS) for HR or NHEJ repair 
efficiency using the Beckton Dickinson (Accuri) C6 flow cytometer and BD Accuri software.  
Results were normalized to controls with untreated samples with I-SceI plasmid 
representing 100% repair (Fig 5-1C). The error bars in all figures represent standard error of the 
mean (SEM) and the P value was calculated by student’s unpaired t test. *p<0.05, **p<0.01, 
***p<<0.01. 
 
Cell survival 
To determine the effect of 1 µM Aβ1-42 upon U2OS cell survival, 70% confluent U2OS cells 
were treated with/without 1 µM Aβ1-42 or Aβ control media for 24 hrs. The cells were suspended 
and counted using the AOPI cellometer counting software (Nexcelom). 300 cells were then 
seeded into a 6 cm dishes in 3mL culture media and incubated at 37°C for 10 days. Colonies 
were fixed and stained with 0.3% crystal violet, and survival (number of colonies) was expressed 
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as a percentage of non-treated colonies. To determine the effect of 1 µM Aβ1-42 upon U2OS IR 
sensitivity, U2OS cells were treated with/without 40 µM 5,6-Dichlorobenzimidazole 1-β-D-
ribofuranoside (DRB; D1916; Sigma) for 24 hrs and/or 1 µM Aβ1-42 or Aβ control media for 5 hrs, 
then seeded onto 6 cm dishes in fresh 3mL culture media. After seeding, cells were exposed to 
irradiation as indicated and incubated for 10 days at 37°C. Colonies were fixed and stained with 
0.3% crystal violet in methanol, and then survival (number of colonies) was expressed as a 
percentage of non-irradiated colonies. 
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test. *p<0.05, **p<0.01, ***p<<0.01. 
 
KillerRed induction 
U2OS-TRE cells were cultured in 35 mm glass-bottom dishes (MatTek, P35GC-1.5-14-C) 
at ~60% confluence 24 h before transfection. For ROS-induced damage, cells were transfected 
with plasmids containing KillerRed (TA-KR/tetR-KR) or cherry controls (TA-cherry/tetR-cherry). 
Light-induced KillerRed activation was done by exposing cells to a 15 W Sylvania cool white 
fluorescent bulb for 15-20 min in a stage UVP (Uvland, CA). A transparent flask filled with cool 
water was placed between the light source and the dishes to avoid temperature fluctuation in the 
exposed dish. Dishes were then covered with foil, and cells were allowed to recover at 37°C for 
indicated times. For γ-H2AX staining, cells recovered for 24 h before fixation. For GFP-BRCA1 
recruitment, cells recovered for 0.5-1 h before fixation.  
The error bars in all figures represent standard error of the mean (SEM) and the P value 
was calculated by student’s unpaired t test or two-way ANOVA and Tukey’s multiple comparisons 
test. *p<0.05, **p<0.01, ***p<<0.01. 
 
 
 43 
CRISPR-Cas9 knockout  
The sgRNAs targeting RAD52 in the human genome were designed on the website 
http://crispr.mit.edu/ and cloned into PX330 vectors (Table 2-1). The sgRNAs were delivered to 
cells by standard transfection. After 24 hours, single cells were spread in 96-well plates or 10 
cm dishes and grown for 10 days to obtain single colonies. The colonies were transferred to 24 
well plates and grown for about one week before genome extraction and genotyping and 
western blot verification. The PCR check primers are also listed (Table 2-1). 
 
Table 2-1 Sequences of sgRNA oligonucleotides 
Oligo Name Sequence 
RAD52 sgRNA L1 up F CACCGCTAGGCTGGAGTCCGACCAG 
RAD52 sgRNA L1 up R AAACCTGGTCGGACTCCAGCCTAGC 
RAD52 sgRNA R1 down F CACCGACCCACAGCAGACTTTCAGC 
RAD52 sgRNA R1 down R AAACGCTGAAAGTCTGCTGTGGGTC 
RAD52 check primer F AATTCATGTGCCTGGAAAGC 
RAD52 check primer R CCCACGTAGAACTTGCCATT 
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3.0 RAD52 is required for RNA-templated recombination repair in post-mitotic neurons 
This chapter is modified from the following collaborative published work: 
Welty, S., Teng, Y., Zhuobin, L., Weixing, Z., Sanders, L., Greenamyre, T., Rubio, M.E., Thathiah, 
A., Kodali, R., Wetzel, R., Levine, A., Lan, L.(2017) RAD52 is required for RNA-templated 
recombination repair in post-mitotic neurons. J Biol Chem. 293(4):1353-1362. 
 
3.1 Introduction 
The most deleterious form of DNA damage, double strand breaks (DSBs), can arise from 
endogenous metabolic processes or exogenous environmental factors such as radiation or 
chemicals [218]. Oxidative damage caused by reactive oxygen species (ROS) and consequent 
DSBs has been implicated in neurodegenerative disorders such as Alzheimer’s disease (AD). 
ROS are generated endogenously by cellular metabolism and a variety of exogenous agents such 
as IR. In studies conducted on replicating cells, it has been found that metabolically-generated 
ROS can cause around 10,000 oxidative lesions per day [87].  
ROS-induced damage predominantly leads to base or deoxyribose modifications that lead 
to single strand breaks (SSBs). DSBs can arise due to replication past ROS-induced lesions, or 
when SSBs occur in close proximity [125]. These lesions are repaired either via non-homologous 
end joining (NHEJ) or homologous recombination (HR). In NHEJ, the broken DNA ends are 
processed/digested and then directly ligated, potentially leading to nucleotide deletions and 
consequent frameshift mutations. Thus, NHEJ is considered to be error-prone [123]. HR utilizes 
undamaged DNA templates in order to direct error-free repair of the damaged strands. It has long 
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been assumed that HR can only take place during the late S/G2 phases of the cell cycle where 
sister chromatids are present as templates [174]. However, recent studies in terminally 
differentiated cells have revealed an RNA-templated HR repair mechanism of DSBs at active 
transcription sites during the G0/G1 phase (transcription coupled homologous recombination-TC-
HR). For this mechanism to occur, Cockayne syndrome B (CSB) protein is recruited to an actively 
transcribed damage site, followed by recruitment of RPA, RAD51, RAD51C, and RAD52; then, 
repair occurs utilizing the nascent RNA template produced by active transcription [177]. An RNA-
templated, RAD52 directed mechanism of HR has also been reported in yeast [191]. However, it 
is not known if the transcription dependent HR pathway exists in neurons. Except in the 
hippocampus and striatum, most neurons in the adult human brain are terminally differentiated 
and non-dividing, and therefore are assumed to be incapable of utilizing HR for DSB repair [175, 
176].  
In this study, utilizing our site-specific damage induction systems, we measured the 
recruitment of TC-HR-associated repair protein RAD52 to sites of DNA damage with and without 
transcription inhibition. We found that post-mitotic neurons employ this RNA-based 
recombinatorial mechanism for the DNA damage response. We also discovered preferential 
binding of RAD52 protein to R-loops, DNA:RNA hybrid structures present during active 
transcription [195], as further evidence of RAD52’s role in TC-HR. Given our finding of the novel 
TC-HR DNA repair mechanism in post-mitotic cells, we wondered if this mechanism might be 
affected in neurodegenerative disorders such as AD. We utilized Aβ1-42, neurotoxic oligomers 42 
amino acids in length that are heavily implicated in AD pathology as they are prone to aggregation 
[219]. We found that Aβ1-42 oligomers downregulate the expression and damage response of the 
essential TC-HR repair protein RAD52. How this dysregulation of DNA repair may significantly 
contribute to the development of neurodegenerative diseases such as AD is discussed below. 
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3.2 Results 
3.2.1  DNA repair factors are recruited to laser-induced damage in neurons 
To understand how non-dividing neurons repair oxidative DNA damage, we first verified 
that the primary rat cortical neurons utilized for experimentation were post-mitotic. Some findings 
have shown a link between cell cycle activation in post-mitotic neurons and a DNA damage 
response leading to apoptosis [132]. Therefore, we probed DIV12 neuronal cell cultures with anti-
phosphorylated histone H3 (Ser10) before and after DSB inducing gamma irradiation (Fig. 3-1A) 
[220]. Studies have shown a correlation between this phosphorylated histone H3 (Ser10) and 
mitotic chromosome condensation during early prophase, suggesting anti-phosphohistone H3 
can be used as a mitosis-specific marker [221]. Here we observed no evidence of mitosis in the 
primary cortical neurons as compared to replicating U2OS cells before or 24 hr after 5Gy gamma 
irradiation. We utilized U2OS human osteocarcinoma cells to represent mitotic cells due to their 
robustness in cell culture, fast growth, and high transfection rate. This cell line has also been 
established in a stable cell line for use with KillerRed fusion proteins as discussed in Chapter 
1.5.4.  
Prior studies in our lab have shown that terminally differentiated cells utilize an RNA-
templated homologous recombination mechanism for repair of DSBs in the G0/G1 phase of the 
cell cycle. This mechanism of repair can only occur with active transcription [177]. Members of 
our lab have also previously demonstrated by terminal deoxynucleotidyltransferase-mediated 
dUTP-biotin nick end labeling assay that our laser light microirradiation system induces DNA 
strand breaks in cells [222]. Therefore, we utilized 405 nm laser microirradiation to induce DSBs 
at localized sites in single cells which makes it possible to observe repair protein recruitment in 
non-dividing cells [214] (Fig 3-1B) [220]. We then investigated recruitment of GFP-tagged repair 
proteins specific to particular repair pathways including XRCC1 (DNA single strand break repair 
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[SSBR]), KU70 (NHEJ), and RAD52 (HR) (Fig. 3-1C) [220]. In this experiment, we were surprised 
to find the recruitment of TC-HR repair protein RAD52 to sites of damage in post-mitotic neurons 
despite the neurons’ lack of a sister chromatid to utilize as a template for homologous repair.  
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Figure 3-1 Post-mitotic neurons recruit TC-HR associated protein RAD52. 
A. Rat DIV12 cortical neurons and U2OS cells were treated with and without 5Gy irradiation and probed 
with anti-phospho-Histone H3 (Ser10) antibody. Error bars indicate the SEM of three separate experiments 
(n=100), and the p values were determined by using Student’s unpaired two-tailed t test. Cortical neurons 
do not show expression of phosphorylated H3 (Ser10). B. Schematic of 405 nm scan laser system for 
induction of DSBs in single cells where single cell nuclei are targeted with 100-500 msec of laser 
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microirradiation to visualize and quantify GFP-tagged repair protein recruitment at damage sites. C. 
Recruitment of GFP-tagged DNA repair proteins XRCC1 (SSBR), KU70 (NHEJ), and RAD52 (HR) at sites 
of DNA damage in U2OS and DIV12 cortical neurons before and 1 min after 100 msec-500 msec laser 
microirradiation. Error bars indicate the SEM of two separate experiments, and the p values were 
determined by using Student’s unpaired two-tailed t test (***p<<0.01). D. BrdU incorporation after 100 msec 
laser microirradiation with and without pre-treatment with DRB (40 μM) for 24 hr in U2OS and DIV12 cortical 
neurons. Error bars indicate the SEM of three separate experiments, n=10, and the p values were 
determined by using Student’s unpaired two-tailed t test (***p<<0.01). 
3.2.2  DNA incorporation at sites of damage is affected by transcription inhibition 
We next investigated whether transcription inhibition would affect the repair synthesis 
process of HR in post-mitotic neurons. We pre-treated the cells with the RNA polymerase II 
inhibitor DRB, (5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole), which inhibits transcription 
elongation, and analyzed the incorporation of bromodeoxyuridine (BrdU), a synthetic analog of 
thymidine, into newly repaired DNA after laser damage. Importantly, the replication-mediated 
incorporation of BrdU into genomic DNA of post-mitotic neurons does not occur. Therefore, BrdU 
staining in neurons should indicate repair-triggered BrdU incorporation. This incorporation was 
significantly decreased after DRB treatment (Fig. 3-1D) [220], indicating that active transcription 
and a nascent RNA template are necessary for HR repair in post-mitotic neurons.  
3.2.3  Transcription inhibition or RNase H treatment reduces the recruitment of RAD52 in 
neurons 
RAD52 can be utilized in HR or a mutagenic repair process known as single strand 
annealing (SSA). SSA, which results in a deletion rearrangement between homologous repeating 
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sequences, is independent of active transcription [120]. Since our prior study indicated that the 
RAD52 dependent, RNA-templated recombination only occurs at sites of active transcription 
[177], we then tried to determine whether post-mitotic neurons utilize this particular 
recombinational mechanism for error-free repair of DSBs. To determine if active transcription is 
necessary for the damage response of RAD52 in post-mitotic neurons, we pretreated cells with 
RNA polymerase II inhibitors DRB, which  inhibits transcription elongation, or α-amanitin, which 
inhibits transcription initiation and elongation (Fig. 3-2A&B) [220]. Both inhibitors block 
transcription, thereby preventing the production of an mRNA template for use in RNA-templated 
HR. We found that after inhibiting RNA polymerase II with both inhibitors, recruitment of RAD52, 
an essential factor for RNA-templated recombinational repair, was significantly reduced at sites 
of laser damage in post-mitotic neurons. This supports our findings that RNA-templated HR in 
post-mitotic neurons requires active transcription to take place. 
To further establish that the recombination in post-mitotic neurons is associated with RNA-
templated repair, we examined the effect of RNase H, an endo-ribonuclease that specifically 
degrades the RNA strand in an RNA-DNA hybrid structure, on the recruitment of RAD52 (Fig. 3-
2C) [220]. After treatment with RNase H, RAD52 recruitment was significantly reduced at sites of 
laser damage in post-mitotic neurons. To test whether the effects of the RNase H assay were 
actually due to the enzyme activity or if the results were due to the conditions of the experiment, 
we measured recruitment of SSBR protein XRCC1 after RNase H treatment. Since XRCC1 does 
not rely on an RNA strand, recruitment of XRCC1 should not be affected by RNase H activity. As 
evidenced in Fig. 3-2D [220], we did not see significant reduction in XRCC1 activity after RNase 
H treatment. Combined, these results confirm that a nascent RNA template is necessary for HR 
repair to occur in post-mitotic neurons. 
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Figure 3-2 Transcription inhibition reduces template-driven repair in post-mitotic neurons. 
A. Recruitment of RAD52 before and 1 min after 200-500 msec laser microirradiation treatment with and 
without pre-treatment with RNA polymerase II inhibitor (40 μM) DRB for 24 hr in U2OS cells and DIV12 
ventral neurons. B. Recruitment of RAD52 before and 1 min after 200-500 msec laser microirradiation 
treatment with and without pre-treatment with RNA polymerase II inhibitor (100 μg/mL) α-amanitin for 0.5 
hr in U2OS cells and DIV12 ventral neurons. Error bars indicate the SEM of two separate experiments, 
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n=10, and the p values were determined by using Student’s unpaired two-tailed t test (***p<<0.01).C. 
Recruitment of RAD52 before and 1 min after 500 msec laser microirradiation treatment with and without 
pre-treatment with 15 U. RNase H for 15 min in U2OS cells and DIV12 ventral neurons. Error bars indicate 
the SEM of two different experiments, n=10, and the p values were determined by using Student’s unpaired 
two-tailed t test (**p<0.01; ***p<<0.01). D. Recruitment of XRCC1 before and 1 min after 500 msec laser 
microirradiation treatment with and without pre-treatment with 15 U. RNase H for 15 min in U2OS cells and 
DIV12 cortical neurons. Error bars indicate the SEM of two different experiments, n=10, and the p values 
were determined by using Student’s unpaired two-tailed t test. 
3.2.4  RAD52 binds to an R-loop substrate and preferentially binds to ssRNA 
RAD52 protein has been demonstrated to bind DNA structures with DSBs [223, 224]. 
Since previous studies from others and our study both indicate that RAD52 is involved in RNA-
templated recombination repair, we tested the affinity of RAD52 for RNA related substrates by 
electrophoretic mobility shift assay (EMSA). Results show that purified human RAD52 protein 
efficiently binds both single-stranded (ss) DNA and RNA (Fig. 3-3A&3-3B) [220], though its 
binding affinity to ssRNA is higher than that of ssDNA. Binding affinities of RAD52 to double-
stranded (ds) DNA and RNA (Fig. 3-3C&3-3D) [220] are significantly reduced compared to ss 
substrates (Fig. 3-3G) [220]. Interestingly, RAD52 has slightly higher affinity to RNA:DNA hybrid 
duplex than dsDNA and dsRNA (Fig. 3-3E) [220]. Furthermore, RAD52 has a higher binding 
affinity to R-loop substrates (Fig. 3-3F) [220], the damage-prone structures at transcriptionally 
active sites in the genome [195], than hybrid structures. These in vitro results are consistent with 
the possibility that RAD52 may bind ssRNA and the co-transcriptional R-loop upon transcriptional 
stress in post-mitotic neurons. 
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Figure 3-3 RAD52 preferentially binds ssRNA and R-loop substrate. 
Electrophoretic mobility shift assay (EMSA) to test binding of RAD52 protein to: A. ssDNA, B. ssRNA, C. 
dsDNA, D. dsRNA, E. RNA:DNA hybrid, and F. R-loop substrate (10 nM). G. Representative graph of A-F. 
RAD52 preferentially binds ssRNA and R-loop. 
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3.2.5  Discussion 
In this study, we first discovered that recruitment of HR factor RAD52 to sites of DNA 
damage is dependent upon the presence of a nascent mRNA template for HR, indicating the 
existence of a novel RNA-templated recombinational repair pathway in post-mitotic neurons. We 
also discovered that RAD52 preferentially binds ssRNA and has direct affinity for R-loops, 
reinforcing the involvement of RAD52 in TC-HR repair of double strand breaks. Utilization of this 
less error-prone pathway is essential for non-dividing neurons to maintain their genomic integrity 
when faced with environmental pressures such as metabolically-induced oxidative damage and 
other endogenous and exogenous stressors.  
Considering the fact that terminally differentiated, post-mitotic neurons must survive a 
human lifetime, utilizing an error-prone pathway such as NHEJ would subject the cells to 
potentially lethal genomic errors. In a study on cell-cycle arrested cells, it was found that NHEJ 
activity was responsible for approximately half of all replication-independent frameshift mutations, 
primarily due to deletions. Mutant yeast cells deficient for HR (RAD54-deletion) did not exhibit an 
increase in the number of of replication-independent mutations in the cell-cycle arrested cells, but 
RAD52-deletion mutants did [225]. This study confirms both the mutagenic nature of NHEJ, and 
the possibility of a RAD-52 dependent pathway such as TC-HR that counteracts the frameshift-
producing NHEJ pathway. 
Although post-mitotic neurons do not face the acquisition of mutations after replicating 
DNA past DNA lesions as commonly occurs in mitotic cells, DNA DSBs still pose massive risks 
to essential genes when not repaired. Failure to completely repair DNA may result in cellular 
senescence or apoptosis as a means for the cell to cope with an excess of damage and avoid 
malignant transformation [226, 227]. However, unrepaired cells may also accumulate mutations 
that affect genes involved in regulating apoptosis, cell division, and DNA repair. If proliferating 
stem and neural progenitor cells incur mutations due to unrepaired DNA during development, 
 55 
disease may later develop as a result of disrupted essential genes passed down through cell 
division or if tumor suppressing or oncogenes are no longer properly regulated [228]. In post-
mitotic neurons, mutations may contribute to neuronal dysfunction and apoptosis, as seen in the 
pathology of AD where the cerebral cortex and hippocampus suffer extensive neuronal loss [229]. 
Many neurodegenerative pathologies have also been linked to genetic deficiencies in DNA repair 
genes. For example, in ataxia-telangiectasia (A-T), a mutation in the P 13 kinase A-T mutated 
(ATM) protein, which is activated by DNA DSBs and is responsible for phosphorylating numerous 
downstream targets involved in DNA repair, cell cycle arrest, and apoptosis, causes individuals 
to experience higher rates of cancer and undergo neurodegeneration before the age of five [230-
232]. New research has suggested that the neuronal loss observed in AD may also result from 
partial loss of ATM function as AD pathology progresses [233]. 
Study of repair mechanisms in post-mitotic neurons is essential if we are to understand 
the complex nature of neurodegenerative diseases. While certain genetic aberrations may 
constitute a significant role in contributing to physiological aspects of AD such as the APOEε4 
allele and its association with increased AD risk, other contributing factors remain unknown [234]. 
These factors may include deficiencies in DNA repair directly related to environmental exposures 
or internal processes such as the production of ROS during cellular metabolism or neuronal 
activity. 
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4.0 BRCA1 plays an important role in TC-HR 
4.1 Introduction 
BRCA1 is known to participate in numerous cellular processes including canonical HR. It 
has been shown to coexist with RAD51 and BARD1 in a complex named the BRCA1-BRCA2 
Containing Complex (BRCC) which has E3 ubiquitin ligase activities responsible for regulating 
DNA damage response factors [235]. Although its precise mechanism in canonical HR is still 
debated, cells deficient in BRCA1 are more sensitive to IR and contain numerous chromosomal 
aberrations, possibly due to unrepaired DNA damage [236, 237]. BRCA1 also has been found to 
play a role in transcription coupled repair (TCR). Here, BRCA1 accumulates at actively 
transcribed UV damage sites dependent upon Cockayne syndrome B protein (CSB). It 
polyubiquitinates CSB for degradation [238, 239]. The main types of DNA damage induced by UV 
irradiation are the formation of cyclobutane pyrimidine dimers (CPD) and (6-4) photoproduct 
adducts which can be repaired via nucleotide excision repair (NER) through either TCR or global 
genome repair (GGR). BRCA1 is primarily found in the cytoplasm during the majority of the cell 
cycle, but can localize to the nucleus following DNA damage during S phase [240]. How this 
affects post-mitotic neurons and BRCA1’s damage response has not been previously 
investigated. Importantly, however, the TC-HR pathway for DSB repair is dependent upon the 
recruitment of CSB and RAD52. Because the role of BRCA1 in TC-HR is entirely unknown, we 
sought to elucidate the role of BRCA1 in TC-HR.  
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4.2 Results 
4.2.1  Recuitment of BRCA1 to transcriptionally active sites of DNA damage dependent 
on active transcription 
We utilized the DNA damage at active transcription sites (DART) system, illustrated in Fig. 
1-5, to study molecular responses to light-induced DNA damage at single genomic loci with 
controllable transcription [184, 185]. In this system, U2OS TRE cells are exposed to white light 
for 15 min, and the transiently transfected tet-repressor (tetR)- or tet-transcription activator (TA)-
tagged KR proteins (tetR-KR or TA-KR) induce similar amounts of ROS-induced DSBs at 
transcriptionally inactive or active sites, respectively in real time. Recruitment of repair proteins to 
these sites of damage can then be measured by examining relative fluorescence intensity using 
fluorescent tagged proteins or immunofluorescent staining techniques. We first examined the 
recruitment of BRCA1 protein to both TA-KR and tetR-KR sites and control TA-cherry and tetR-
cherry sites after light activation (Fig. 4-1A). BRCA1 was recruited to sites of both active 
transcription and inactive transcription after damage induction, and was not recruited to control 
TA-cherry or tetR-cherry sites. To determine that BRCA1 recruitment to TA-KR damage sites is 
dependent upon active transcription and not DNA damage alone, we utilized the RNA polymerase 
II inhibitors DRB (5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole) and α-amanitin to examine 
BRCA1 recruitment to sites of active and inactive transcription after transcription inhibition (Fig. 
4-1C). We found a significant reduction in BRCA1 recruitment at TA-KR sites after both 
treatments, but only saw a reduction in BRCA1 recruitment at tetR-KR sites after DRB treatment. 
These results with α-amanitin treatment indicate that BRCA1 is preferentially recruited to DNA 
damage sites where active transcription is taking place. Experimentally, DRB treatment is 24 hrs 
and α-amanitin is 0.5 hrs. Hypothetically the longer DRB treatment could inhibit production of 
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BRCA1 protein, thus affecting its recruitment regardless of transcription activity at the damage 
site. In order to determine if the reduction in BRCA1 recruitment to tetR-KR sites was due to 
overall BRCA1 protein reduction due to DRB treatment, we performed a western blot to 
investigate BRCA1 protein level discrepancies between the two treatments. Western blot analysis 
of GFP-tagged BRCA1 in U2OS cells after the same treatments shows a significant reduction in 
BRCA1 protein after DRB treatment, but not a reduction in BRCA1 protein after α-amanitin 
treatment (Fig. 4-1B). These results indicate that the observed reduction in BRCA1 recruitment 
at TA-KR damage sites is not due to a reduction in protein alone, but is due to the inhibition of 
active transcription. Due to the confounding effect of DRB upon overall protein reduction over a 
24hr time period, we chose to utilize α-amanitin as the sole transcription inhibitor for all future 
experiments. 
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Figure 4-1 BRCA1 recruitment to TA-KR damage sites dependent upon active transcription. 
A. GFP-BRCA1 and TA-KR/tetR-KR transfected U2OS-TRE cells were illuminated with 15 W fluorescent 
white light for 15 min for damage induction. B. Western blot of GFP-BRCA1 in U2OS cells with and without 
DRB (40 µM) for 24 hr or α-amanitin (100 μg/mL) for 0.5 hr. Error bars indicate the SEM of three separate 
experiments, n=10, and the p values were determined by using Student’s unpaired two-tailed t test 
(*p<0.05). C. GFP-BRCA1 and TA-KR/tetR-KR transfected U2OS-TRE cells were pretreated with DRB (40 
µM) for 24 hr or α-amanitin (100 μg/mL) for 0.5 hr. Error bars indicate the SEM of three separate 
experiments, n=10, and the p values were determined by using Student’s unpaired two-tailed t test 
(***p<<0.01). (Of note, other treatments were included on these western blots, but were not relevant to this 
study; thus the cropped images.) 
 
Previous studies have shown that BRCA1’s C- and N-terminus are required for BRCA1’s 
DSB DNA repair response [241]. In order to elucidate BRCA1’s role in TC-HR, we utilized an N-
terminal mutant, C61G, which contains a mutation in the highly conserved RING finger domain 
and has been associated with numerous breast and ovarian cancers [242, 243]. This mutation 
abolishes BRCA1’s association with BARD1 protein and inhibits its E3 ubiquitin ligase activity 
[241]. Although the BRCA1/BARD1 E3 ligase activity is poorly understood, BRCA1 and BARD1 
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are required to recruit RAD51 and BRCA2, repair proteins involved in canonical HR [244]. We 
found that recruitment of C61G to light induced TA-KR sites was not significantly enriched over 
tetR-KR sites (Fig. 4-2A). C61G also did not demonstrate significantly reduced recruitment to TA-
KR or tetR-KR sites compared to full length BRCA1 (Fig 4-2B).  
Treatment with the polymerase II inhibitor α-amanitin, however, significantly reduced the 
recruitment of C61G to TA-KR sites (Fig. 4-2A). Compared to full length BRCA1, C61G also 
demonstrated significantly reduced recruitment to actively transcribed TA-KR damage sites (Fig 
4-2B). These results indicate that BRCA1’s recruitment at actively transcribed damage sites is 
dependent on its E3 ubiquitin ligase activity and BARD1 binding.  
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Figure 4-2 C61G recruitment dependent upon BARD binding site. 
A. GFP-BRCA1 C61G mutant and TA-KR or tetR-KR transfected U2OS-TRE cells were pretreated with α-
amanitin (100 μg/mL) for 0.5 hr. and illuminated with 15 W fluorescent white light for 15 min for damage 
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induction. B. GFP-BRCA1 C61G mutant or full length GFP-BRCA1 and TA-KR or tetR-KR transfected 
U2OS-TRE cells were pretreated with α-amanitin (100 μg/mL) for 0.5 hr. Error bars indicate the SEM of 
three separate experiments, n=10, and the p values were determined by using Student’s unpaired two-
tailed t test (***p<<0.01, *p<0.05). 
4.2.2  BRCA1 recruitment at damage sites with active transcription independent of RAD52 
In humans, BRCA1 is a key protein that promotes DSB repair by HR over NHEJ. Although 
the precise mechanisms of pathway choice in DSB repair are still poorly understood, a crucial 
step lies in the 53BP1-dependent barrier that prevents DNA resection. Studies have shown that 
BRCA1 relieves this barrier by promoting 53BP1 phosphorylation [245].  
In yeast, RAD52 is a ring-shaped oligomer that helps load RAD51 onto RPA coated 
ssDNA to promote single-strand annealing [246, 247]. It also acts in strand capture during the 
invasion step of HR [151, 248]. RAD52 is conserved between yeast and humans, primarily in the 
N-terminal region [249]. However, RAD52’s precise role in HR in human cells is poorly 
understood. A recent study has shown that RAD52 binds to the RPA-ssDNA pre-synaptic complex 
in canonical HR in humans and is displaced after the addition of RAD51 [216]. Previous research 
in the Lan lab using the DART system showed that the C-terminus of RAD52, not its DNA-binding 
N-terminal domain, is required for its DNA damage response to actively transcribed regions in 
TC-HR. RAD52 also directly binds Cockayne syndrome B (CSB) protein, the precursory protein 
required for TC-HR factor recruitment [177]. As we discovered in Chapter 3, RAD52 recruitment 
to DNA damage sites is reduced by transcription inhibition in post-mitotic neurons in the G0/G1 
phase of the cell cycle. Purified RAD52 protein also preferentially binds ssDNA and R-loops, 
further implicating RAD52 early in the TC-HR pathway.  
In canonical HR, BRCA1 binds BARD1 to firm a RING heterodimer. This heterodimer then 
interacts with BRCA2 which binds RAD51 to promote strand invasion [250, 251]. Since we 
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discovered BRCA1’s active transcription dependent DNA damage recruitment is dependent upon 
its BARD1 binding activity much like in canonical HR, we wanted to investigate further to 
determine where BRCA1 functions in TC-HR in relation to RAD52. We hypothesized that BRCA1 
functions upstream of RAD52 due to its BARD1 binding activity.  
To determine if BRCA1 functions dependently or independently of RAD52 in TC-HR, we 
utilized a stable U2OS TRE RAD52 knockout cell line developed by members of the Lan lab using 
CRISPR Cas9 (Fig. 4-3A). To make this knockout, sgRNA pairs were targeted to delete exon 4 
in RAD52 which causes a frameshift and premature stop of RAD52 protein. Since exon 4 also 
contains an alternative start codon, targeting exon 4 eliminates all the isoforms of RAD52. Using 
the DART system, we found that after light induction, there was no significant difference in 
recruitment of transiently transfected GFP-tagged BRCA1 to inactively transcribed DNA damage 
sites (tetR-KR) over actively transcribed damage sites (TA-KR) in the RAD52 KO (Fig. 4-3B). No 
significant difference in GFP-BRCA1 recruitment was seen even when compared to wt controls 
at TA-KR sites or tetR-KR sites (Fig 4-3C). This demonstrates that without RAD52, cells will still 
recruit BRCA1 at sites of damage with active transcription. When treated with RNA polymerase II 
inhibitor α-amanitin, however, recruitment to TA-KR sites was more significantly reduced than 
recruitment of BRCA1 to tetR-KR sites (Fig. 4-3B). This only further demonstrates the role of 
BRCA1 in the active transcription dependent TC-HR pathway. Together these results indicate 
that BRCA1 recruitment at DNA damage sites with active transcription is independent of RAD52. 
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Figure 4-3 BRCA1 recruitment at actively transcribed sites independent of RAD52. 
A. Schematic of RAD52 KO in U2OS-TRE cell line and western blot knockout verification. B. GFP-BRCA1 
and TA-KR/tetR-KR transfected U2OS-TRE cells were pretreated with and without α-amanitin (100 μg/mL) 
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for 0.5 hr and illuminated with 15 W fluorescent white light for 15 min for damage induction. Error bars 
indicate the SEM of three separate experiments, n=10, and the p values were determined by using 
Student’s unpaired two-tailed t test (***p<<0.01,*p<0.05). C. GFP-BRCA1 and TA-KR/tetR-KR transfected 
U2OS-TRE cells and RAD52 KO U2OS-TRE cells were illuminated with 15 W fluorescent white light for 15 
min for damage induction. Error bars indicate the SEM of three separate experiments, n=10, and the p 
values were determined by using Student’s unpaired two-tailed t test. 
4.2.3  Discussion 
We have found that BRCA1 is preferentially recruited to actively transcribed DNA damage, 
and that this activity is independent of BRCA1’s BARD1 binding and its E3 ligase activity. 
Additionally, we discovered that BRCA1 recruitment to actively transcribed damage sites is 
independent of RAD52 in the TC-HR pathway.  
Further experiments are necessary in order to define BRCA1’s role in TC-HR. Many of 
these have already proven to be difficult due to the toxicity of BRCA1 overexpression after 24hrs. 
We have found that in cancer cell lines and post-mitotic neurons, GFP-BRCA1 overexpression 
induces cell death after more than 24hrs, resulting in observable transfection efficiencies of less 
than 50% after such time. Thus, some experiments have been reduced to shorter treatment times 
after transient transfections. Future studies would necessitate the use of stable cell lines or 
knockouts.  
In order to further elucidate RAD52 and BRCA1’s roles in TC-HR vs canonical HR, siRNA 
for BRCA1 and RAD52 should be used in U2OS-TRE cells to investigate γ-H2AX retention at TA-
KR sites after KillerRed induction at 0h, 1h, 4h, 24h, and 48h timepoints of recovery. Greater 
intensity of the γ-H2AX foci at TA-KR sites at later timepoints than controls will indicate unrepaired 
DSBs after the knockdown of RAD52, BRCA1, and RAD52/BRCA1 together. The inability to repair 
DSBs with either or both repair protein knockdowns will indicate which proteins are essential for 
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DSB repair at actively transcribed sites of DNA damage. A survival assay can also be conducted 
with the same knockdowns and increasing doses of gamma irradiation ranging from 1Gy, 3Gy, 
and 5Gy. The knockdown with fewer surviving colonies of U2OS cells after 7-10 days will indicate 
which repair protein(s) is/are necessary for repair fidelity. Western blots will verify all knockdowns.  
What needs to be considered in these experiments is that both RAD52 and BRCA1 
function in other DNA repair pathways besides DSB repair as mentioned in Chapter Three. The 
siRNA knockdowns may therefore affect these pathways as well. BRCA1 knockdowns may also 
affect processes other than DNA repair, such as apoptosis, confounding survival assays. Previous 
studies have found that ectopic expression of BRCA1 led to cell cycle arrest at the G2/M stage of 
the cell cycle in MCF-7 cells or apoptosis in U2OS cells [252-254]. Indeed, experiments involving 
transient transfection of GFP-BRCA1 and its consequent overexpression for longer than 48 hr 
time periods have led to decreased transfection efficiencies (<10%) in both U2OS cells and 
neurons. This implies that the overexpression of BRCA1 can lead to toxicity. Its knockdown should 
be monitored for similar effects using assays to measure apoptosis and proper controls. Also, 
since BRCA1 is not only localized to the nucleus, nuclear fractionation prior to western blotting 
may help in isolating DNA repair associated BRCA1 for specific investigations into its repair 
properties. 
Recruitment of repair factors to DNA damage sites is essential for their roles in the DNA 
damage response. Further studies are indeed necessary to elucidate both BRCA1 and RAD52 
repair activity in the TC-HR pathway such as comet assays and γ-H2AX retention to measure 
DSB repair after damage. In regards to performing repair function, however, demonstrating 
recruitment at DNA damage sites is significant in order to show the initiation of the repair process. 
For example, other investigations have been conducted into major repair pathways such as MMR 
using laser microirradiation and HeLa cells to demonstrate that the recruitment of key MMR repair 
proteins MSH2, MSH3, and MSH6 occurs at UVDE-induced SSBs in a poly(ADP-ribose)-
dependent manner [255]. This study is significant because MMR is used to repair base 
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mismatches and mismatched loops typically formed during DNA replication. Unless a lesion 
contains a mismatch, MMR associated factors do not directly bind to DNA damage sites such as 
DNA strand breaks or UV-induced damage. The experiments conducted in this study indicate that 
certain MMR repair factors are, indeed, recruited to SSB damage sites prior to repair via MMR. 
BRCA1 is a complex and important protein, but further defining its role in TC-HR will help 
to better understand how Aβ negatively affects the DNA damage response. The following section 
of this dissertation introduces this next concept.  
 
 68 
5.0 Aβ1-42 oligomers affect the DNA damage response of BRCA1 and RAD52 
This chapter is expanded from the following collaborative published work: 
Welty, S., Teng, Y., Zhuobin, L., Weixing, Z., Sanders, L., Greenamyre, T., Rubio, M.E., Thathiah, 
A., Kodali, R., Wetzel, R., Levine, A., Lan, L. (2017) RAD52 is required for RNA-templated 
recombination repair in post-mitotic neurons. J Biol Chem. 293(4):1353-1362. 
 
5.1 Introduction 
Aβ is produced by proteolytic cleavage of the transmembrane protein APP, which is 
expressed in numerous tissue types. Low concentrations (pM) of Aβ have been confirmed via 
microdialysis in the interstitial fluid of normal brains, but higher concentrations in the nM-µM range 
lead to neurotoxicity and neuronal death [48, 49]. It was normally assumed that blood circulating 
Aβ originates from Aβ produced within brain regions that then crosses the blood-brain barrier 
[256, 257].  
Aβ can also be produced in peripheral tissues and secreted into the blood. Platelets can 
produce Aβ in a similar manner to neurons, and it’s also been shown that skin fibroblasts, skeletal 
muscles, and cerebrovascular smooth muscle cells can also produce Aβ [258-262]. In a recent 
study using a model of parabiosis, or surgically conjoined mice which share circulating blood, it 
was shown that this peripherally generated Aβ circulating in the bloodstream can contribute to AD 
pathology. This model used a transgenic AD mouse conjoined with a wild type littermate and 
found evidence of human Aβ plaques, hyperphosphorylated tau tangles, and AD-related 
pathologies such as neurodegeneration and impaired hippocampal long term potentiation in the 
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wild type mouse after 12 months of parabiosis [263]. Importantly, these studies show that Aβ 
metabolism in both the brain and periphery can contribute to the development of late stage AD 
pathology.  
Measurement of this circulating Aβ is often used to help diagnose AD and is believed to 
be a more progressive method to keep track of patients showing signs of cognitive decline in the 
early stages of the disease. Traditional methods include measuring Aβ1-40 and Aβ1-42 levels from 
the cerebral spinal fluid (CSF), or visualizing amyloid or tau pathologies in the brain via positron 
emission tomography (PET) [264]. Testing blood plasma for Aβ1-40 and Aβ1-42 is currently possible 
with sensitive measurements such as mass spectrometry, but is not commonly used for patients 
due to the lower levels of Aβ found in the blood [265]. What needs to be considered, however, is 
that measurements of circulating Aβ levels in the CSF and plasma may be confounded due to 
their origin.  
Cellular responses to DNA damaging agents are not all the same depending upon stages 
of the cell cycle, cell type, regional specificity in the mammalian body, and also age. Cell cycle 
dependent responses to DSBs have been discussed in Chapter Two regarding canonical HR, 
TC-HR, and NHEJ. In addition, there is research showing cell type, age specific, and 
regional/tissue differences in DNA damage responses to DSBs. For example, studies have shown 
that differentiated mouse embryonic fibroblasts predominantly utilize error-prone NHEJ to repair 
DSBs. Undifferentiated mouse embryonic stem cells (ES), which would give rise to all cell types 
and globally affect the organism, preferentially use the more error-free canonical HR in order to 
increase their repair fidelity even when NHEJ repair proteins are artificially overexpressed [266]. 
Regarding regional specificity, lung basal stem cells were shown to use NHEJ to repair DSBs 
more efficiently than alveolar progenitor cells [267]. Epidermal stem cells are highly proficient in 
NER to repair UV induced DNA lesions, and individuals with deletions in XPA/XPC repair proteins 
are susceptible to squamous cell carcinoma [268].   
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 With these studies in mind, the research in this chapter was undertaken in order to 
investigate the effects of extracellular toxic Aβ1-42 oligomers on DNA DSB repair processes in 
mitotic and post-mitotic in vivo cellular models. My hypothesis was that Aβ1-42 would downregulate 
the recruitment of TC-HR associated proteins, thus leading to the inhibition of repair. This section 
demonstrates that Aβ1-42 negatively affects DSB repair activity dependent upon active 
transcription, reduces the TC-HR associated RAD52 protein and HR/TC-HR associated repair 
protein BRCA1 recruitment to DNA damage sites, reduces RAD52 protein levels, increases R-
loop formation, and decreases DSB repair efficiency. 
5.2 Results 
5.2.1  Aβ1-42 sensitizes cells to IR in the absence of active transcription 
The accumulation of Aβ1-42 in AD is correlated with DNA damage induced by oxidative 
stress. As mentioned in Chapter 4, a recent study has shown that high concentrations of Aβ1-42 (1 
µM) in mitotic mouse hippocampal neuron cultures and in brain samples from AD patients were 
correlated with reduced levels of BRCA1 and increased levels of DSB marker γ-H2AX [13]. 
BRCA1’s role in DSB repair and other cellular processes has been discussed in Chapter 2. 
However, it is not known whether Aβ1-42 affects the major DSB repair pathways: the error-prone 
NHEJ pathway and the less error-prone HR pathway.  
We investigated the effects of Aβ1-42 on overall HR and NHEJ in dividing U2OS cells using 
the HR (DR-GFP) and NHEJ (Ej5-GFP) reporter assays [269, 270] (Fig. 5-1A&B). For the HR 
reporter assay, the DR-GFP cell line utilizes an I-SceI recognition site inserted into a GFP coding 
sequence to create a nonfunctional GFP transgene. A wild type GFP fragment has been inserted 
downstream of the transgene. After transfection of an I-SceI expressing plasmid, a DSB is created 
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at the I-SceI cleavage site. If successful HR occurs, fully functional GFP is restored which can be 
detected by fluorescence activated cell sorting (FACS). For the NHEJ assay, the Ej5-GFP cell 
line utilizes a GFP coding sequence interrupted by a puromycine gene which is flanked by I-SceI 
recognition sites. After transfection of the I-SceI expressing plasmid, a DSB is induced at both 
sites, and if NHEJ occurs, a fully functional GFP is restored which can be detectable by FACS. 
For these experiments, both assays were treated with 1 µM Aβ1-42 to determine its effect on each 
pathway. 
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Figure 5-1 HR and NHEJ reporter assays. 
A. Schematic of the DR-GFP reporter used to measure HR efficiency in U2OS cells. B. Schematic of the 
Ej5-GFP reporter used to measure NHEJ efficiency in U2OS cells. C. Representative FACS sample data 
of the DR-GFP reporter cells without I-SceI endonuclease (a.), with I-SceI endonuclease (b.), and I-SceI 
endonuclease and 5 hr 1 μM Aβ treatment. D. DR-GFP reporter cells were pretreated with 1μM Aβ for 5 hr 
and expression of GFP was measured by flow cytometry. Error bars indicate the SEM of three separate 
experiments and the p values were determined by using Student’s unpaired two-tailed t test. E. Ej5-GFP 
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reporter cells were pretreated with 1μM Aβ for 5 hr and expression of GFP was measured by flow cytometry. 
Error bars indicate the SEM of three separate experiments and the p values were determined by using 
Student’s unpaired two-tailed t test. Adapted from [220] with permission from the publisher. 
 
Prior to use, Aβ1-42 samples were investigated via western blot and Transmission electron 
microscopy (TEM) to verify that they contained oligomers (Fig. 5-2A&B, 5-3) [220].  
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Figure 5-2 Aβ1-42 solution contains low molecular weight oligomers. 
A. Western blot of Aβ1-40 & Aβ1-42 monomeric controls, titrated Aβ1-42 oligomeric solution incubated at 37℃ 
for 24 hrs, and Aβ1-42 oligomeric solution control not incubated at 37℃, all probed with anti-6E10 antibody. 
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B. Characterization of Aβ1-42 aggregates at 50 μM with transmission electron microscopy (TEM).  The length 
of the segments are 0.2μm in the upper panels.  The length of the segments are 50 nm in the lower panels.  
The lower panels represent higher magnification images. 
 
 
Figure 5-3 1 μM Aβ1-42 solution frozen at -20C contains oligomers. 
Comparative Western blots of increasing concentrations of Aβ1-42 standard aliquot previously stored in 
DMSO at -80C, 1 μM Aβ1-42 stored at -20C, and 1 μM Aβ1-42 stored at 4C., all probed with anti-6E10 
antibody. 
 
We found that Aβ1-42 did not significantly affect HR or NHEJ in dividing cells (Fig. 5-1D&E). 
This is most likely due to the ability of the dividing cells to utilize canonical HR in addition to TC-
HR for DSB repair.   
In order to determine whether Aβ1-42 would affect the TC-HR pathway, we utilized the RNA 
polymerase II inhibitor DRB to disrupt transcription in U2OS cells and measured clonogenic 
survival against ionizing radiation (IR). 1 µM Aβ1-42 alone negatively affects overall U2OS survival 
(Fig. 5-4A), and as shown in Fig. 5-4B, DRB treatment alone renders cells more sensitive to IR. 
However, the addition of 1 µM Aβ1-42 to DRB treatment did not further increase cells’ sensitivity to 
IR (Fig. 5-4C). This indicates that the activity of Aβ1-42 upon cell survival is dependent upon active 
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transcription, leading us to question its involvement in the downregulation of the more specific 
TC-HR pathway. 
 
Figure 5-4 1 μM Aβ sensitizes dividing cells to IR. 
A. U2OS cells were pre-treated with 1 μM Aβ for 24 hr. Colony forming assay was performed, and the 
surviving fraction is shown. Error bars indicate the SEM of three separate experiments, and the p values 
were determined by using Student’s unpaired two-tailed t test (***p<<0.01). B. U2OS cells were pre-treated 
for 24 hr with or without DRB (40 µM), then irradiated with IR at the indicated dose. Colony forming assay 
was performed and the surviving fraction is shown. Error bars indicate the SEM of three separate 
experiments, and the p values were determined by using Student’s unpaired two-tailed t test (***p<<0.01). 
C. U2OS cells were pre-treated for 24hrs with or without DRB (40 µM), then treated with or without 1 μM 
Aβ for 5 hr and irradiated with IR at the indicated dose. Colony forming assay was performed, and the 
surviving fraction is shown. Error bars indicate the SEM of three separate experiments, and the p values 
were determined by using Student’s unpaired two-tailed t test. Adapted from [220] with permission from the 
publisher. 
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5.2.2  High concentrations of Aβ1-42 downregulate the damage response of RAD52 and 
BRCA1 in post-mitotic neurons 
After determining that post-mitotic neurons utilize TC-HR, we wondered if Aβ1-42 might 
compromise the repair efficiency of specific proteins involved in TC-HR in non-dividing neurons. 
The Mucke group had previously discovered that Aβ1-42 reduced protein concentrations of BRCA1 
in hippocampal neurons [13]. These mitotic neurons are known to exhibit neurogenesis in adult 
humans and would primarily utilize canonical HR to repair DSBs [13]. Genome-wide microarrays 
have also found an increase in AD pathology correlating with the downregulation of RAD52 
expression in cortical and hippocampal brain regions of AD model mice [271]. To test whether 
Aβ1-42 oligomers would exhibit the same repressive effects upon the post-mitotic neurons, we 
treated primary rat cortical neuron cell cultures with 1 µM Aβ1-42 and investigated the DDR 
response and protein amounts of TC-HR associated proteins BRCA1 and RAD52 (Fig. 5-5&5-6).  
Here we found that BRCA1 recruitment to laser damage sites was significantly reduced in 
the presence of high concentrations (1 µM) of Aβ1-42, but not lower concentrations (1 nM) (Fig. 5-
5B). Interestingly, BRCA1 protein expression was not significantly reduced in cortical neuron 
cultures after increasing concentrations of Aβ1-42 or 5 hr and 24 hr treatment with 1 µM Aβ1-42 (Fig. 
5-5A). 
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Figure 5-5 1 μM Aβ reduces BRCA1 recruitment to damage sites. 
A. Western blot of endogenous BRCA1 of DIV12 primary rat cortical neurons with and without increasing 
concentrations of Aβ oligomers for 5 hr, and with and without 5 hr and 24 hr 1μM Aβ treatment. B. 
Recruitment of BRCA1 before and 1 min after 500 msec laser microirradiation treatment with and without 
1 nMand 1 μM Aβ for 5 hr in DIV12 cortical neurons. Error bars indicate the SEM of two separate 
experiments, n=10, and the p values were determined by using Student’s unpaired two-tailed t test 
(**p<0.01). 
 
Western blot analysis showed that 1 µM Aβ1-42 reduced overall RAD52 protein levels in 
post-mitotic neurons (Fig. 5-6A), but γ-H2AX expression was not significantly increased 
compared to untreated controls (Fig. 5-6C). After 24 hr of treatment, 1 µM Aβ1-42 significantly 
reduced RAD52 recruitment to damage sites in both post-mitotic neurons and U2OS cancer cells 
(Fig. 5-6B). This demonstrates inhibition of RAD52 repair protein dynamics by 1 µM Aβ1-42. The 
effects of 1 µM Aβ1-42 on γ-H2AX will be further explored in sections 5.2.4 and 5.2.5.  
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Figure 5-6 1 μM Aβ reduces RAD52 protein and recruitment to damage sites. 
A. Western blot of RAD52 in DIV12 cortical neurons with and without 1 pM, 1 nM, 1 μM Aβ treatment for 5 
hr. B. Recruitment of RAD52 before and 1 min after 500 msec laser microirradiation treatment with and 
without 1 μM Aβ for 24 hr in U2OS and DIV12 cortical neurons. Error bars indicate the SEM of two separate 
experiments, n=10, and the p values were determined by using Student’s unpaired two-tailed t test 
(***p<<0.01). C. Western blot of endogenous 𝛾𝛾-H2AX in DIV12 rat cortical neurons with and without 1 pM, 
1 nM, 1 μM Aβ treatment for 5 hr. Error bars indicate the SEM of three separate experiments and the p 
values were determined by using unpaired two-tailed Student’s t test. Adapted from [220] with permission 
from the publisher. 
 
To verify the specificity of Aβ1-42 oligomers, we also observed recruitment of GFP-tagged 
repair proteins specific to other repair pathways including XRCC1 (DNA single strand break repair 
[SSBR]) and KU70 (NHEJ) after treating primary rat cortical neuron cell cultures with 1 µM Aβ1-42 
(Fig 5-7.). We found that Aβ1-42 did not reduce XRCC1 or Ku70 recruitment to damage sites after 
5 hr treatments or 24 hr treatments. 
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Figure 5-7 1 μM Aβ does not reduce XRCC1 and Ku70 recruitment to damage sites. 
Recruitment of XRCC1 and KU70 before and 1 min after 100 msec and 500 msec laser microirradiation 
treatment with and without 1 μM Aβ for 5 hr in U2OS and DIV12 cortical neurons. Error bars indicate the 
SEM of two separate experiments, n=10, and the p values were determined by using Student’s unpaired 
two-tailed t test. 
 
The Aβ1-42 preparations used in this project are a mixture of oligomeric and monomeric 
intermediates, so it is difficult to ascertain which precise species of Aβ1-42 is responsible for the 
downregulatory properties demonstrated [272]. The prepared Aβ1-42 solution consists of 
approximately a 50:50 ratio of monomers and oligomers as confirmed by size exclusion 
chromatography. In solution, these monomers and oligomers can aggregate and will pellet when 
centrifuged. In order to determine what fraction of the Aβ1-42 solution exerted its toxic effect upon 
BRCA1 recruitment, we first performed a dose response curve to determine optimal concentration 
conditions (Fig. 5-8A). At 0.5 µM and 1.0 µM, Aβ1-42 reduced BRCA1 recruitment to sites of laser 
damage similarly in post-mitotic neurons. Next, we treated cells with the pelleted and supernatant 
fractions of the Aβ1-42 solution and found that the supernatant fraction containing monomers and 
 81 
oligomers of Aβ1-42, but not the aggregated forms of Aβ1-42, was responsible for BRCA1 
recruitment reduction in neurons (Fig. 5-8B). 
 
 
Figure 5-8 Soluble fraction of 1 μM Aβ affects repair protein recruitment. 
A. Dose response curve measuring BRCA1 recruitment 1 min after 500 msec laser microirradiation 
treatment with indicated Aβ concentrations for 5 hr in DIV12 cortical neurons. Error bars indicate the SEM 
of two separate experiments, n=10, and the p values were determined by using Student’s unpaired two-
tailed t test (*p<0.05; **p<0.01). BRCA1 recruitment to damage sites was significantly reduced in post-
mitotic neurons after 0.5 μM and 1 μM Aβ treatment. B. Recruitment of BRCA1 before and 1 min after 500 
msec laser microirradiation treatment with and without 1 μM Aβ supernatant or resuspended pellet for 5 hr 
in DIV12 cortical neurons. Error bars indicate the SEM of two separate experiments, n=10, and the p values 
were determined by using Student’s unpaired two-tailed t test (**p<0.01). 
 
5.2.3  Increased Aβ1-42 concentration leads to R-loop formation 
Unpublished studies in the Lan lab have indicated that increased oxidative stress induces 
global R-loops, damage prone structures at active transcription sites. Through use of the DART 
system these studies have shown that R-loops are inducible at active transcription sites. Aβ1-42 
oligomers have been associated with ROS production through numerous mechanisms previously 
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mentioned such as the Fenton reaction, copper binding, and its methionine residue as discussed 
in Chapter One. Therefore, we hypothesized that overproduction of Aβ1-42 oligomers and the 
consequent ROS lead to increased R-loops. This in turn leaves more surface area of DNA 
exposed to breakage, thus compromising overall genomic stability. 
To verify this hypothesis, we treated wild type U2OS TRE cells with high concentrations 
of Aβ1-42 (1µM) and investigated R-loop formation using anti-S9.6 antibody staining (Fig. 5-9A&5-
9B). Anti-S9.6 antibody is a mouse monoclonal antibody generated against a φX714 
bacteriophage-derived synthetic DNA-RNA antigen which can recognize DNA-RNA hybrids. It 
has been verified for use to recognize the DNA-RNA hybrid formed during active transcription and 
is commonly used to detect R-loops [194]. We found that treatment with Aβ1-42 significantly 
increased the frequency of R-loops at actively transcribed DNA damage sites compared to 
controls (Fig. 5-9B). This demonstrates that high concentrations of Aβ1-42 exacerbate the ROS 
induced R-loop formation of activated KillerRed. 
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Figure 5-9 1 μM Aβ increases R-loops. 
A. Diagram of R-loop formation during active transcription. B. TA-KR and tetR-KR transfected U2OS-TRE 
cells were pre-treated with 1 μM Aβ for 24hrs and cells were illuminated with 15 W fluorescent white light 
for 15 min for damage induction. R-loop formation was determined by co-localization of anti-S9.6 antibody 
to damage sites. Error bars indicate the SEM of two separate experiments, n=10, and the p values were 
determined by using Student’s unpaired two-tailed t test (*p<0.05). C. TA-KR transfected U2OS-TRE cells 
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were pre-treated with 1 μM Aβ for 24 hr. Cells were illuminated with 15 W fluorescent white light for 15 min 
for damage induction, allowed to recover for 4hr or 24hr, then stained with anti-γ-H2AX antibody. Error bars 
indicate the SEM of two separate experiments, n=10, and the p values were determined by using two-way 
ANOVA and Tukey’s multiple comparisons test. 
 
5.2.4  Increased Aβ1-42 delays γ-H2AX expression 
Within a few minutes of DSB formation, H2AX, a variant of the histone H2A, is rapidly 
phosphorylated in the vicinity of the break by the ATM or DNA-PK kinases [273]. This 
phosphorylated form, termed γ-H2AX, is essential for cell cycle checkpoint activation and the 
recruitment of downstream DSB repair factors, although some studies show it is not required for 
the initial break recognition step [274-277]. It has been hypothesized that γ-H2AX is involved in 
chromatin remodeling in order to allow for repair factors to access the damaged DNA. These 
findings have been confirmed by studies that show H2AX-/- cells exhibiting radiosensitivity and 
genomic instability and also double p53 and H2AX KO mice rapidly developing tumors [278, 279]. 
γ-H2AX has, therefore, been used extensively as a marker for DSBs in both immunofluorescent 
staining assays and western blots [280]. In radiobiology, the ratio of DSBs correlates to γ-H2AX 
foci in a 1:1 ratio, although its use as an indicator for DSB repair has been debated [273, 280]. 
One study that compared wild-type and Ku80 deficient mice argued that at low levels of IR 
damage (e.g.-2Gy), γ-H2AX expression and foci retention could be used to indicate DSB repair. 
Higher levels of DNA DSB inducing damage (e.g.-10Gy) produced conflicting results [281]. Other 
studies such as those produced by the Lan lab examining γ-H2AX foci retention after damage as 
an indication of efficient repair have shown consistent results. Typically, γ-H2AX retention is 
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strongest at approximately 2-4hrs after damage induction and is significantly reduced after 24-
48hrs, indicating a completion of repair [177, 282].  
In order to determine if Aβ1-42 inhibits overall DSB repair efficiency, we treated U2OS cells 
with 1µM concentrations of Aβ1-42 for 24hrs and investigated γ-H2AX expression and retention 
after recovery from 3Gy gamma irradiation treatment (Fig. 5-10A-D&5-11&5-12). Western blot 
analysis indicates a delay in γ-H2AX protein production in the early recovery stages of 1hr and 
4hr with the most significant reduction at the 4hr timepoint (Fig. 5-10A-D). (Of note, these results 
represent soluble γ-H2AX. Chromatin-associated γ-H2AX at repair sites may not have been 
completely released in lysis buffer due to lack of benzonase treatment.) There was no significant 
difference in γ-H2AX expression between non-irradiated control and non-irradiated samples 
treated with 1µM concentrations of Aβ1-42 for 24hrs (Fig. 5-11). However, analysis of γ-H2AX foci 
retention, an indicator of DSB resolution, shows no difference in the number of cells with reduced 
γ-H2AX foci after 24hrs and 48hrs (Fig 5-12). Specifically, cells treated with 1µM concentrations 
of Aβ1-42 for 24hrs and irradiated with 3Gy of gamma irradiation showed no retention of γ-H2AX 
foci after 24hrs or 48 hrs as compared to untreated controls. Together, these data indicate that 
Aβ1-42 interferes with early stages of DSB repair, but not overall DSB repair.  
We also investigated γ-H2AX retention at sites of active transcription in U2OS-TRE cells 
after treating cells with 1µM concentrations of Aβ1-42 for 24hrs (Fig 5-9C). Analysis of γ-H2AX foci 
retention showed no significant differences between treated samples and controls at 0 hr, 4 hr, 
and 24 hr timepoints. This further indicates that Aβ1-42 does not interfere with DSB resolution at 
actively transcribed sites of DNA damage. 
Survival assays have demonstrated that 1µM concentrations of Aβ1-42 for 24hrs 
significantly reduce cell survival (Fig. 5-4A), even in mitotic cell populations that are capable of 
utilizing canonical HR and NHEJ for DSB repair. This supports our findings that Aβ1-42 reduces 
the localization of early acting DSB repair proteins RAD52 and BRCA1 at DNA damage sites. 
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Such inhibition may lead to failure to repair and resultant cell death, contributing to the 
neurodegenerative pathology of AD. However, more studies are necessary because the reduction 
of γ-H2AX itself does not necessarily correlate directly with cell death. 
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Figure 5-10 1µM Aβ1-42 delays γ-H2AX expression after IR in mitotic cells. 
U2OS cells were pre-treated with and without 1 μM Aβ for 24 hrs. Cells were then treated with 3Gy of 
gamma irradiation and allowed to recover for A. 1 hr, B. 4 hrs, C. 24 hrs, or D. 48 hrs at 37C, then probed 
via western blot with antibodies for anti-γ-H2AX. Error bars indicate the SEM of two separate experiments, 
and the p values were determined by using two-way ANOVA and Tukey’s multiple comparisons test 
(*p<0.05). 
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Figure 5-11 Aβ1-42 does not alter γ-H2AX expression in U2OS cells without DNA damage. 
Western blot of endogenous γ-H2AX before and after 24hrs of Aβ1-42 treatment. Error bars indicate the 
SEM of two separate experiments, and the p values were determined by using Student’s unpaired t-test. 
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Figure 5-12 1µM Aβ1-42 does not lead to retention of γ-H2AX foci after IR in mitotic cells. 
U2OS cells were pre-treated with and without 1 μM Aβ for 24 hrs. Cells were then treated with 3Gy of 
gamma irradiation and allowed to recover for 1 hr, 4 hrs, 24 hrs, or 48 hrs at 37C, then stained with 
antibodies for anti-γ-H2AX. Error bars indicate the SEM of two separate experiments, n=100, and the p 
values were determined by using two-way ANOVA and Tukey’s multiple comparisons test. 
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5.2.5  Discussion 
This section has shown that Aβ1-42 negatively affects HR in a transcriptionally dependent 
manner, inhibits RAD52 and BRCA1 recruitment to DNA damage sites, reduces RAD52 repair 
protein in post-mitotic neurons, increases R-loop formation, and inhibits γ-H2AX expression early 
following DNA damage. These experiments also indicate Aβ1-42 differentially affects repair proteins 
depending upon the protein itself and the model system utilized. For example, in regards to 
RAD52, in primary rat cortical neurons, endogenous RAD52 protein is reduced and its recruitment 
is downregulated after Aβ1-42 treatment (Fig 5-6A). In human U2OS cells, however, as evidenced 
in Fig 5-13 endogenous RAD52 protein is not reduced following Aβ1-42 treatment.  
 
Figure 5-13 1 μM Aβ1-42 does not affect RAD52 protein level in U2OS cells. 
U2OS cells were pre-treated with and without 1 μM Aβ for 24 hrs. Cells were then then probed via western 
blot with antibodies for anti-RAD52. Error bars indicate the SEM of two separate experiments, and the p 
values were determined by using unpaired Student’s t test. (Of note, other treatments were included on 
these blots, but were not relevant to this study; thus the cropped images.) 
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RAD52 DNA damage response recruitment is negatively affected in both cell lines after 
Aβ1-42 treatment, however (Fig 5-6B). This points to dysregulation of RAD52 protein, and perhaps 
its oxidation by Aβ1-42. One method to verify this is to investigate RAD52 protein after Aβ1-42 
treatment for oxidation, such as evidenced by carbonyl groups as described in Chapter 2. A simple 
method is to quantify overall change in carbonyl content using a colorimetric assay. These assays 
utilize 2,4-Dinitrophenylhydrazine (DNPH) to react with protein carbonyls. The derivatization of 
the carbonyl results in a modified protein that can be measured at 375nm [283, 284]. To measure 
oxidized protein products in low concentrations (µg) like RAD52, an antibody-based ELISA assay 
should be used. This type of assay quantifies the DNP-bound protein immunologically using an 
anti-DNP antibody [111, 285]. Immunoblotting techniques using western blot to determine the 
species of oxidized protein do not produce accurate determinations of carbonyl concentrations, 
but can be used to compare relative increase/decrease in amounts as compared to untreated 
samples when all appropriate controls are used [283].  
 Another experiment that will need to be conducted following the investigation of γ-H2AX 
retention at DNA damage sites with active transcription as well as western blots illuminating 
expression of γ-H2AX after treatment with Aβ1-42 is a comet assay. This assay utilizes lysed cells 
and agarose gel to measure DSBs. The DNA forms supercoiled loops and migrates through the 
gel by electrophoresis, and once imaged by fluorescence microscopy, presents as “comets” with 
the intensity of the comet tail relative to the head representing the number of DNA strand breaks 
[286]. Hypothetically, Aβ1-42  treatment should induce more DSBs, and after time, more DSBs 
should remain, correlating with an increased expression of γ-H2AX.  
Aβ1-42 may not inhibit successful DSB repair, but if it delays the initial response due to 
downregulation of essential DSB repair proteins and early repair factors this could lead to cell 
death or use of an alternate pathway like NHEJ which could lead to error prone repair. 
Experiments using primary rat cortical neurons showed a trend towards an increase in γ-H2AX 
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protein after Aβ1-42 treatment, though it was not statistically significant (Fig 5-6C). Western blots 
of U2OS cells also showed no increase in γ-H2AX protein after 24hrs of Aβ1-42 treatment (Fig 5-
11). The differences in γ-H2AX expression may be due to model organism type (rat vs human), 
cell type (neuron vs carcinoma), and region specificity (cortical vs bone). It is therefore necessary 
to conduct more experiments with a consistent cell line (preferentially post-mitotic neuronal 
cultures) to investigate how Aβ1-42 affects DSB repair and if Aβ1-42 forces these cells to 
preferentially utilize NHEJ or other repair pathways over TC-HR. It is impossible to fully block cells 
from using TC-HR because this pathway is not completely defined. However, cells may be guided 
to preferentially use NHEJ over HR by using siRNA such as for BRCA1 & BRCA2 or RAD52.  
Recent studies using molecular dynamics simulations have also shown that oxidized 
residues can induce conformational changes in Aβ, promoting less aggregation [287]. This would 
imply that oxidative damage to Aβ could reduce its toxicity and may have mitigated its effect upon 
U2OS cells in the experiments involving IR (Fig. 5-10&5-12). If this is the case, then proper 
controls must be utilized in future studies, such as samples treated with Aβ1-42 only and no IR.  
A cyclohexamide (CHX) chase assay can be performed to investigate the effects of Aβ1-
42 upon RAD52 protein stability. CHX inhibits the translocation step in protein synthesis, 
preventing more protein from being made. After treatment with CHX, proteins are degraded over 
time by regulatory processes such as RNA decay and proteolysis. This allows for visualization of 
protein levels via western blotting techniques in order to determine the protein half-life and stability 
[288-292]. Hypothetically, if Aβ1-42 is leading to an increase in RAD52 protein turnover (e.g.-
RAD52 is being degraded more rapidly), with CHX treatment in addition to Aβ1-42 treatment, 
RAD52 protein levels will be more significantly reduced more quickly than in untreated cells. More 
experiments also need to be conducted following the CHX chase assay such as qPCR and 
proteasome inhibition. The qPCR following Aβ1-42 treatment will demonstrate whether transcription 
is affected or mRNA levels are disrupted by Aβ1-42. Proteasomal inhibition in conjunction with the 
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CHX chase assay will show if RAD52 is degraded via the ubiquitin proteasomal pathway, and if 
Aβ1-42 affects the proteasome or ubiquitination of RAD52 in some manner.  
Although much work is still to be done, these findings which demonstrate how Aβ1-42 
negatively affects the initial DNA damage response in post-mitotic cells and contributes to AD 
pathology are an important first step in understanding early contributing factors to the 
development of AD disease. 
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6.0 Final Discussion & Future Directions 
The experiments outlined in this thesis have all culminated in evidence of post-mitotic 
neurons utilizing a novel pathway of DSB repair, TC-HR, in order to maintain lifelong genomic 
integrity when faced with the excessive stress induced by endogenous and exogenous sources 
of ROS. Specifically, this thesis has shown that BRCA1 plays a role in the TC-HR pathway 
dependent upon its BARD1 binding site and independent of RAD52 recruitment. This thesis has 
also shown that Aβ1-42 significantly affects the early stages of the DDR by inhibiting γ-H2AX and 
RAD52 expression and RAD52 and BRCA1 protein recruitment to DNA damage sites. It has also 
shown that Aβ1-42 induces R-loop formation at DNA damage sites with active transcription, 
exposing DNA to further damage. These results provide new insights into the mechanisms with 
which post-mitotic neurons maintain their genome and demonstrate how dysregulation of TC-HR 
by Aβ1-42 in early stages of AD can lead to downregulation of DNA repair.   
Our hypothetical model proposes a negative feedback loop of Aβ1-42 on genomic stability 
(Fig. 6-1). Excessive oxidative damage and consequent DNA DSBs induce γ-secretase to 
mediate the expression of β-secretase (BACE1), cleaving the transmembrane amyloid precursor 
protein (APP) into Aβ1-42  monomers which later form soluble oligomers. Re-uptake of Aβ1-42 for its 
aforementioned antioxidant properties leads to further intracellular ROS production and the 
consequent downregulation of recombinational repair proteins as we have outlined in this study. 
This deficit in high fidelity repair leads to genomic instability, which potentially promotes neuronal 
impairment and eventual apoptosis, both processes implicated in the neurodegenerative 
pathology of AD [293]. 
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Figure 6-1  Model for Aβ1-42 effect upon high fidelity DNA damage repair in post-mitotic neurons. 
Oxidative damage to DNA leads to the induction of beta and gamma secretases, which cleave pro-amyloid 
(APP) to Aβ1-42. The hypothetical model shows how oxidative damage leads to APP cleavage, consequent 
intracellular damage, and repair protein inhibition. This cycle leads to a downregulation in high fidelity 
recombinational repair and genomic instability, and may further contribute to neurodegenerative pathology. 
 
Currently we understand very little of how Aβ1-42 acts upon DNA repair proteins. As 
outlined in previous chapters, this mechanism is in need of much further investigation. What 
follows are some specific questions that this thesis has generated and several experimental 
approaches to address them. 
 
6.1 What is the specific role of BRCA1 in the TC-HR pathway? 
The findings mentioned in Chapter 4 that BRCA1 is implicated in TC-HR dependent upon 
its BARD1 binding and independent of RAD52 recruitment raises numerous questions about the 
role of BRCA1 in this pathway. For instance, whether BRCA1 still forms a complex with PALB2 
and BRCA2 in order to promote RAD51 filament formation in TC-HR is unknown [140]. Also, 
BRCA1 poly-ubiquitinates CSB in the TCR pathway, but whether BRCA1 interacts with CSB in 
TC-HR has yet to be determined [238, 239]. Ubiquitination is the process where the 76-amino-
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acid polypeptide ubiquitin is covalently attached to other proteins singly (mono-ubiquitination) or 
in the form of polyubiquitin chains (poly-ubiquination) by the actions of ubiquitin E1, E2, and E3 
ligase proteins [294]. Some of these modifications target the proteins for proteasome-based 
degradation while others serve as docking platforms for DDR-based protein assembly. BRCA1 
could be involved in the poly-ubiquitination of CSB via its E3 ligase activity. This E3 ligase activity, 
as mentioned earlier, is dependent upon BARD1 binding, and in canonical HR involves BRCA2 
and RAD51 as well [244, 245]. CSB is essential for TC-HR and is poly-ubiquitinated at the 
resolution of DNA DSB repair [177]. Hypothetically, a loss of BRCA1 E3 ligase function targeted 
to CSB could have significantly negative impact upon DNA repair in post-mitotic neurons 
dependent upon the TC-HR pathway for DSB repair outside of the error-prone NHEJ pathway. 
This would be seen in retention of CSB at the site of damage and the failure of transcription to 
resume. 
Considering the involvement of BRCA1 in numerous pathways aside from canonical HR 
and TC-HR such as apoptosis and cell cycle checkpoints, initial investigations would have to focus 
upon the E3 ligase activity of BRCA1 on CSB in TC-HR. Co-IP experiments must be conducted 
in order to determine if the two proteins interact in the TC-HR pathway after DNA damage. Since 
HR commonly occurs in the S phase of the cell cycle and TCR occurs with UV damage, cells can 
be arrested in the G0/G1 phase of the cell cycle to drive them into either TC-HR or NHEJ for DSB 
repair. These experiments can be conducted with human cells such as HeLa arrested in G0/G1 
using double thymidine block following Lan lab protocols, or with primary rat cortical post-mitotic 
neurons such as those used in prior experiments [177]. Confirmation of cell cycle arrest and cell 
cycle phase will be done via FACS. If BRCA1 and CSB interact in G0/G1 arrested cells as 
determined by Co-IP, western blots with anti-ubiquitin antibodies can be utilized to determine if 
the CSB protein associated with BRCA1 is ubiquitinated, and recovery timecourses after DNA 
damage (IR) spanning 0h, 1h, 4h, 8h, 12h, and 24h can be conducted to determine if this 
ubiquitination increases over time. 
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To determine the binding region with which CSB interacts with BRCA1, GFP-tagged CSB 
fragments will be utilized in Co-IPs experiments with HA-tagged full length BRCA1. For the Co-
IPs, GFP-tagged CSB fragments will be transiently transfected along with HA-tagged BRCA1 
plasmids, and Co-IPs run with western blots after DNA damage (IR) to determine which CSB 
fragments and therefore which region(s) of CSB binds to BRCA1. Anti-ubiquitin antibodies will be 
used to measure the differences in CSB ubiquitination as well. CSB fragments used will be regions 
of amino acids 1-336, 337-590 (acidic domain), 510-960, 961-1399, 1400-1493, and full length. 
Survival assays using CSB knockout cell lines engineered with CRISPR as recently demonstrated 
in currently unpublished experiments in the Lan lab will be used. These CSB KO cell lines 
transiently transfected with the CSB fragments will be conducted to determine how inhibiting CSB 
ubiquitination affects overall cell survival. 
Similar experiments will be conducted to determine the binding region with which BRCA1 
interacts with CSB. GFP-tagged BRCA1 fragments will be used in Co-IP experiments with HA-
tagged full length CSB, both transiently transfected. Cells will be damaged with IR and western 
blots run to determine which region(s) of BRCA1 binds to CSB. GFP-tagged BRCA1 fragments 
utilized will be the following mutants and regions of amino acids: ∆305-770 (NLS deletion), ∆775-
1292, ∆1-302 (N-terminal deletion), ∆1527-1863 (C-terminal deletion), 303-1526 (N- & C-terminal 
deletion), 1-304 (N-terminus only), 1528-1863 (C-terminus only) (Fig. 6-2) [241].  
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Figure 6-2 BRCA1 and GFP-BRCA1 mutants. 
A. Important BRCA1 binding regions and domains. RING, Ring domain; NES, nuclear export sequence; 
NLS, nuclear localization sequence; BRCT, BRCA1 C-terminal domain. B. Diagram of GFP-tagged BRCA1 
mutants and truncations. 
 
These experiments will determine if BRCA1 is involved in the regulation of CSB in TC-HR, 
and if dysregulation of BRCA1 negatively affects the TC-HR pathway and overall cell survival. If 
the hypothesis is true that BRCA1 helps regulate CSB in TC-HR, then this will become a 
significant starting point to discovering a more precise role of BRCA1 in TC-HR. 
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6.2 Define the mechanism of Aβ1-42 on repair proteins using a more physiologically 
relevant model system 
A significant discovery in this thesis was that high concentrations of Aβ1-42 reduced protein 
concentrations of RAD52 in post-mitotic primary rat cortical neuronal cultures, but not mitotic 
U2OS osteocarcinoma cell cultures (Fig.5-6A&5-13). High concentrations of Aβ1-42 also only 
affected recruitment of specific DNA repair protein to damage sites. Notably, RAD52 and BRCA1 
recruitment to DNA damage sites were reduced after treatment with Aβ1-42, while Ku70 and 
XRCC1 recruitment remained unaffected (Fig. 5-5B&5-6B&5-7). Essential considerations for 
differences in these results include 1. Potential selective Aβ1-42 binding to proteins to affect their 
activity, 2. differences in model systems (rat vs human cells), 3. variability in cell types (neurons 
vs cancer cells, etc.), and 4. mitotic stages and differential use of repair pathways as discussed 
in Chapter 1.5.  
If Aβ1-42 directly binds repair proteins and alters their conformation, this could prevent them 
from being able to respond to DNA damage and bind to other partners, or it could lead them to 
be degraded by the proteasome due to their misfolding. The selectivity of Aβ1-42 and its effect 
upon repair proteins could be due to the need of particular binding regions or charges on the 
repair protein itself. If certain repair proteins lack these, they may not interact with Aβ1-42 at all. 
Those that do interact directly with Aβ1-42 could accumulate aggregates of Aβ1-42 and continue to 
misfold. This self-propagation of Aβ1-42 aggregates has been documented in numerous studies 
and has been termed the “prion-like effect” [295-297]. However, it has not been explored in 
regards to the effect of Aβ1-42 upon repair proteins. Such a phenomenon should be considered in 
this circumstance. It can be initially explored using AD mouse models and immunohistochemistry 
to investigate Aβ1-42 aggregates and their co-localization with repair proteins.  
The difference in RAD52 expression may also hypothetically be influenced by the mitotic 
U2OS cell preferential use of NHEJ to repair DSBs, and their ability to utilize canonical HR, which 
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is independent of RAD52 (as discussed in Chapter 1). Post-mitotic neurons, however, cannot 
utilize canonical HR, and so must rely predominantly on NHEJ for DSB repair. However, as 
outlined in Chapter 1.5.4 and in my research in Chapter 3, post-mitotic neurons can also utilize 
TC-HR for DSB repair, which has been associated with repair protein RAD52. As prior studies 
have implicated an important role for RAD52 in the TC-HR pathway, it would be reasonable to 
speculate that the reduction in RAD52 protein levels after Aβ1-42 treatment is dependent upon the 
ability to utilize particular DSBR pathways. However, a better model system must be developed 
in order to rule out further complicating variables that could be influencing repair pathway choice 
such as cell type (neurons vs cancer cells), repair protein availability (rat vs human), and 
robustness of particular cell lines (U2OS vs. rat primary cortical neurons).  
Another significant discovery in this research was that high concentrations of Aβ1-42 do not 
lead to γ-H2AX foci retention with or without DNA damage. Contradictory to studies conducted by 
the Mucke group, we also found that the same high concentration of 1µM Aβ1-42 does not lead to 
increased γ-H2AX expression in primary rat cortical neurons or in U2OS osteocarcinoma cells 
(Fig. 5-6C) [13]. The Mucke group utilized mouse cell cultures and AD brain samples from the 
hippocampal region which undergoes neurogenesis and therefore is comprised of mitotic cells. In 
adult humans, the generation of new neurons from a neuronal stem cell pool does not occur 
throughout the entire brain. This process of neurogenesis is thought to be restricted solely to the 
hippocampal region, namely the dentate gyrus, where glia-like precursor cells that express 
neuronal stem cell markers give rise to progenitor cells which develop into the neuronal granule 
cells found in the hippocampal region [298]. Adult neurogenesis consists of four main stages: 
precursor cell stage, early survivor cell stage, post-mitotic maturation stage, late survival stage. 
Within these stages, six distinct milestones can be identified: the radial glia-like precursor cell, 
three progenitor stages of adult neurogenesis with high proliferation activity, post-mitotic 
maturation phase, and the final granule cell (Fig 6-3) [299-304]. The precursor stage involves the 
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expansion of the cell pool with the early survival stage marking the exit from the cell cycle. The 
post-mitotic maturation stage involves the growth of axons and dendrites and synaptogenesis 
with the survival phase covering final adjustments and fine-tuning. The entirety of adult 
neurogenesis in the hippocampus takes ~7 weeks [299]. One of the larger and highly debated 
questions is how similar adult neurogenesis in the dentate gyrus is to embryonic or early post-
natal neurogenesis. The data is not consistent when referring to functionality of neurons in adults 
compared to those produced in the neonatal period (e.g.- comparing action potentials and 
neurotransmitters such as glutamate), speed of maturation of the neurons, and quality and 
quantity of stimuli and memory contents that pass the dentate gyrus [298, 305, 306]. 
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Figure 6-3 Developmental stages in the course of adult hippocampal neurogenesis. 
Precursor phase: A radial glial-like precursor stem cell progresses into progenitor cells. Early postmitotic 
maturation phase: growth of axons, dendrites, and synaptogenesis. Late postmitotic maturation phase: final 
maturation of dendritic spines, fine-tuning. GFAP, Glial fibrillary acidic protein; BLBP, brain lipid-binding 
protein; DCX, doublecortin; PSA-NCAM, polysialilated neural-cell-adhesion molecule; LTP, long term 
potentiation. Adapted from [298] with permission from the publisher. 
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Also relevant is the plasticity of DNA damage repair during neuronal differentiation 
compared to mature neurons. Numerous studies have been conducted that demonstrate 
differentiating neurons downregulate DNA repair compared to post-mitotic neurons [307]. For 
example, neurospheres were used in one study to investigate BER-associated glycosylase OGG1 
activity in neural stem cells compared to differentiating and adult neural cells in mice [308]. 
Researchers found that OGG1 activity was higher in neurospheres derived from newborn mice 
and decreased in those derived from adults and upon differentiation. Post-mitotic cells such as 
neurons have also been found to undergo an extra step prior to apoptosis. They require not only 
the release of cytochrome c from the mitochondria, but the additional step of releasing the X-
linked inhibitor of apoptosis protein (XIAP) which regulates caspases by directly binding them and 
inhibiting their activity. In post-mitotic neurons, studies have found that selective nerve growth 
factor deprivation can relieve XIAP activity through selectively degrading it. DNA damage can 
also overcome XIAP activity through p53-mediated induction of apoptotic peptidase activating 
factor 1 (Apaf-1) [309]. Prior studies have even shown that mouse stem cells lack a G1 checkpoint 
and consequently have shortened G1 and G2 cell cycle phases. As a result they spend over 70% 
of the cell cycle in S phase, implying these cells would utilize canonical HR over NHEJ for DSB 
repair [310, 311].  This would also imply that in the hippocampal region, namely the dentate gyrus, 
dividing stem cells in the precursor stage would favor HR over the typical NHEJ due to cell cycle 
regulation. More research into neuronal cell specificity and which DNA repair pathways are more 
upregulated or downregulated is essential if we are to understand how Aβ1-42 differentially affects 
each neuronal type and why. 
What will be most beneficial for the future is to establish a more physiologically relevant 
model for the investigation of selective neuronal vulnerability in DSB repair in AD. One such model 
is the immortalized hNPC cell line ReNcell VM (ReN). These are human neural progenitor cells 
which, when deprived of specific growth factors, differentiate into neurons astrocytes, and glial 
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cells. When engineered to express human APP with FAD associated mutations and cultured in a 
3D Matrigel environment, they deposit amyloid plaques [312]. Preliminary experiments have been 
conducted in the Thathiah lab utilizing neurosphere cultures of ReN cells passaged onto 2D and 
3D Matrigel cultures. Once differentiated over 16 days, these cell cultures were found to consist 
primarily of neurons (<80%) and astrocytes.  
 
6.2.1  What DNA repair proteins are differentially expressed in neuronal progenitors, 
differentiated neurons, and AD patient brains? 
Experiments using progenitor and differentiated ReN cell cultures will include 
investigations into the nuclear proteome after DNA damage using nuclear fractionation and mass 
spectrometry analysis. Different damaging reagents will be utilized in order to determine what 
significant DNA repair pathways are upregulated and downregulated dependent upon damage 
type (e.g.-global DNA damage using hydrogen peroxide and gamma irradiation vs DNA specific 
damage using phleomycin). Further investigations will also be conducted with extracellular 
applications of Aβ1-42 to determine how Aβ1-42 alters specific DNA repair pathways in progenitor 
vs differentiated neurons. These experiments will help isolate DNA repair proteins according to 
their repair function, specifically BRCA1, by investigating nuclear localized proteins only. 
In regards to regional specificity and its relevance in the pathology of AD, this model 
system can be utilized for these investigations as well. We will determine how to further 
differentiate these ReN cells into specific neuronal types such as glutamatergic or GABAergic 
cells (excitatory and inhibitory subtypes, respectively) and investigate their response to DNA 
damaging agents either as a population or individually using single cell targeting methods 
previously described throughout this thesis.    
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Pittsburgh is also home to the Neuropathy Brain Bank. This branch of the University of 
Pittsburgh Brain Institute provides over 1000 preserved neurodegenerative disease patient brain 
samples for research, including AD and healthy patient samples. We are able to use specific brain 
region tissue to perform nuclear isolation protocol and mass spec analysis in order to compare 
the proteome of regional sections of AD brain tissue versus healthy controls. Once optimized, 
these experiments will allow us to pinpoint specific DNA repair proteins that are upregulated and 
downregulated in brain regions in AD, providing us with genes we can target as knockdowns or 
knockouts in our model ReN system to further explore the origins of AD pathology and how Aβ1-
42 and the dysregulation of essential DNA repair proteins contribute to the development of 
neurodegenerative disease.  
 
6.2.2  How does Aβ1-42 affect DNA repair proteins in neurons? 
Using the more relevant ReN progenitors will also provide the means to better investigate 
the effect of Aβ1-42 on canonical HR and TC-HR in human neuronal cells rather than through use 
of murine models or cancer cells. Since they are immortalized, progenitors can be transfected 
with plasmids containing mutations and post-mitotic ReN cells can be used in the same 
experiments in Chapter 3 to verify their use of TC-HR when canonical HR is unavailable.  
Preliminary studies have already shown that Aβ1-42 negatively affects ReN progenitor 
survival after IR. Optimized survival assays using ReN progenitors can therefore provide more 
relevant insight into the effect of Aβ1-42 on neuronal stem cell populations in the human brain, most 
of which are located in the hippocampal dentate gyrus, but according to controversial studies may 
also be located elsewhere [313].  
The CHX chase assay will provide significant results using the differentiated and 
progenitor ReN cell model as these two systems can be used to compare how Aβ1-42 affects the 
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degradation of TC-HR associated repair proteins RAD52 and BRCA1 as well as other significant 
proteins in cells dependent upon TC-HR (differentiated ReN) versus those capable of using 
canonical HR and TC-HR (progenitor ReN). Few studies have been able to use the same cell line 
for such studies, so these results will be important in profiling details of Aβ1-42 and how it affects 
DNA repair.  
As a measure of DNA repair efficiency, we can use single-cell sequencing after IR and 
Aβ1-42 treatment to determine if Aβ1-42 treated ReN progenitor cells have repaired DNA lesions. 
Failure to repair efficiently will result in regions acquiring deletions, frameshift mutations, point 
mutations, base mismatches, etc. Unrepaired sequences will not match control sequences when 
nucleotide bases are compared within known genomic regions of ReN cells [314, 315]. A 
drawback to this technique is that DNA damage is random and the human genome is incredibly 
large (over 3 billion base pairs). It could take considerable time to verify the presence of 
unrepaired lesions even within the span of known nucleotide sequences. An additional assay to 
detect unrepaired DNA is the HPRT assay. This assay uses human cell culture and relies on 
mutations destroying the functionality of the hypoxanthine phosphoribosyl transferase (HPRT) 
gene, which is located on the X chromosome. Functionality of the gene/protein is tested via 
positive selection using a toxic analogue where HPRT deficient mutants are the surviving viable 
colonies [316]. ReN neuronal progenitor cells are derived from a human male, so contain only 
one X chromosome [317]. This makes it easier to select for loss of function. Performing this HPRT 
assay in conjunction with single-cell sequencing will provide a general measure of global DNA 
repair efficiency after Aβ1-42 treatment in the ReN progenitor cell line. 
Another major question is whether Aβ1-42 is inducing a positive feedback loop through 
production of ROS, triggering more oxidative damage. As discussed in Chapter 1.3.2, Aβ1-42 has 
been implicated in the production of ROS through its activity with free metal ions. In order to 
determine more specifically how Aβ1-42 is causing a positive feedback loop using the ReN cell 
model, the production of ROS after Aβ1-42 treatment must first be investigated. This can be done 
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using both progenitors and differentiated cells in 2D and 3D cultures using a simple ROS detection 
kit (e.g.-Abcam’s ROS/Superoxide Detection Assay Kit- ab139476) to monitor the real-time 
production of ROS via fluorescence microscopy after Aβ1-42 treatment. It will be interesting to see 
if there is a difference in ROS production between ReN progenitors and differentiated neurons, 
implying that uptake of Aβ1-42 may be different as well. Antibodies for Aβ1-42 can be used to 
determine nuclear localization of Aβ1-42 after treatment, indicating Aβ1-42 uptake. However, 
endogenous Aβ1-42 production must be considered to not confound experimental results. In that 
circumstance, APP KO cells can be used, or γ-secretase inhibitors to inhibit APP cleavage as 
described in Chapter 1.3.1. If ROS production and Aβ1-42 production/uptake is increased in 
neuronal progenitors, it implies that undifferentiated neuronal cells are susceptible to damage 
from Aβ1-42 and its consequent ROS, and could pass on deleterious effects of this damage to their 
differentiated progeny. This could contribute to the progression of AD pathology.  
Ultimately this data using the human neuronal ReN cell line will be important in 
demonstrating how Aβ1-42 can affect high fidelity DNA repair both in neuronal precursor cells and 
in differentiated cell populations. It will help to illuminate specifically how and when Aβ1-42 starts 
to contribute to the generation of AD pathology through its effect upon DNA repair pathways. 
Studies that follow may utilize this data to develop preventative therapies to combat the growing 
global threat of AD. 
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